

Washington University
Report on Federal Financial Assistance
Programs in Accordance with Uniform Guidance
For the Year Ended June 30, 2020
Employer Identification Number: 43-0653611

Washington University
Report on Federal Financial Assistance Programs in
Accordance with Uniform Guidance
Index
June 30, 2020

	Page(s)
A. FINANCIAL STATEMENTS AND SUPPLEMENTAL INFORMATION	
Report of Independent Auditors	1-2
Consolidated Financial Statements for the Years Ended June 30, 2020 and 2019.....	3-31
Schedule of Expenditures of Federal Awards	32-52
Notes to Schedule of Expenditures of Federal Awards	53
B. REPORTS ON COMPLIANCE AND ON INTERNAL CONTROLS	
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	54-55
Report of Independent Auditors on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and On Internal Control Over Compliance in Accordance with the Uniform Guidance	56-57
C. SCHEDULE OF FINDINGS AND QUESTIONED COSTS	
Part I – Summary of Auditors’ Results	58
Part II – Financial Statement Findings	59
Part III – Federal Award Findings and Questioned Costs	59
D. SUMMARY SCHEDULE OF PRIOR AUDIT FINDINGS	
Part IV – Summary Schedule of Prior Audit Findings.....	60

Financial Statements and Supplemental Information



Report of Independent Auditors

To the Board of Trustees of Washington University:

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of Washington University and its subsidiaries (the “university”), which comprise the consolidated statements of financial position as of June 30, 2020 and 2019, and the related consolidated statements of activities and cash flows for the years then ended, and the related notes to the financial statements.

Management’s Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ Responsibility

Our responsibility is to express an opinion on the consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the university's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the university's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the university and its subsidiaries as of June 30, 2020 and 2019, and the consolidated changes in their net assets and their cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.



Other Matters

Other Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards for the year ended June 30, 2020 is presented for purposes of additional analysis as required by Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and is not a required part of the consolidated financial statements. The information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated October 2, 2020 on our consideration of the university's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the year ended June 30, 2020. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the university's internal control over financial reporting and compliance.

PricewaterhouseCoopers LLP

St. Louis, Missouri
October 2, 2020

Washington University
Consolidated Statements of Financial Position
June 30, 2020 and 2019

(thousands of dollars)

	2020	2019
Assets		
Cash and cash equivalents	\$ 316,246	\$ 400,100
Investments	10,616,526	9,723,936
Accounts and notes receivable, net	552,592	621,325
Pledges receivable, net	441,909	389,944
Other assets	273,473	272,499
Fixed assets, net	<u>2,902,823</u>	<u>2,736,428</u>
Total assets	<u>\$ 15,103,569</u>	<u>\$ 14,144,232</u>
Liabilities		
Accounts payable and accrued expenses	\$ 575,332	\$ 692,819
Deposits, advances and other	33,388	29,945
Professional liability	91,493	84,236
Deferred revenue and contract liabilities	158,348	150,426
Liabilities under split-interest agreements	38,690	38,806
Government supported student loans	22,671	34,981
Notes and bonds payable	<u>2,415,342</u>	<u>2,064,087</u>
Total liabilities	<u>3,335,264</u>	<u>3,095,300</u>
Net Assets		
Without donor restrictions	5,885,728	5,476,886
With donor restrictions	<u>5,882,577</u>	<u>5,572,046</u>
Total net assets	<u>11,768,305</u>	<u>11,048,932</u>
Total liabilities and net assets	<u>\$ 15,103,569</u>	<u>\$ 14,144,232</u>

The accompanying notes are an integral part of these consolidated financial statements.

Washington University
Consolidated Statements of Activities
June 30, 2020

<i>(thousands of dollars)</i>	Without Donor Restrictions	With Donor Restrictions	June 30, 2020 Total
Revenues			
Tuition and fees	\$ 451,500	\$	\$ 451,500
Endowment spending distribution	351,383	10,489	361,872
Investment return	19,990	1,182	21,172
Gifts	101,843	142,845	244,688
Grants and contracts revenues			
Direct costs recovered	483,265		483,265
Facilities and administrative costs recovered	177,421		177,421
Patient services, net	1,482,562		1,482,562
Auxiliary enterprises - sales and services	102,434		102,434
Educational activities - sales and services	183,974		183,974
Affiliated hospital revenues	146,460		146,460
Other revenue	94,352	2	94,354
Net assets released from restrictions	123,173	(123,173)	-
Total Revenues and other support	<u>3,718,357</u>	<u>31,345</u>	<u>3,749,702</u>
Expenses:			
Compensation expense	2,183,944		2,183,944
Supplies, services, and other	1,103,911		1,103,911
Depreciation expense	201,973		201,973
Interest expense	70,200		70,200
Total expenses	<u>3,560,028</u>	<u>-</u>	<u>3,560,028</u>
Net operating results	<u>158,329</u>	<u>31,345</u>	<u>189,674</u>
Non-operating revenues and (expenses):			
Investment returns net of endowment spending	307,030	171,445	478,475
Permanently restricted gifts		80,184	80,184
Other non-operating	(56,517)	27,557	(28,960)
Non-operating, net	<u>250,513</u>	<u>279,186</u>	<u>529,699</u>
Change in net assets	408,842	310,531	719,373
Net Assets, Beginning of the Year	<u>5,476,886</u>	<u>5,572,046</u>	<u>11,048,932</u>
Net Assets, End of the Year	<u>\$ 5,885,728</u>	<u>\$ 5,882,577</u>	<u>\$ 11,768,305</u>

The accompanying notes are an integral part of these consolidated financial statements.

Washington University
Consolidated Statements of Activities
June 30, 2019

<i>(thousands of dollars)</i>	Without Donor Restrictions	With Donor Restrictions	June 30, 2019 Total
Revenues			
Tuition and fees	\$ 441,915	\$	\$ 441,915
Endowment spending distribution	331,548	9,764	341,312
Investment return	25,983	1,499	27,482
Gifts	137,035	90,201	227,236
Grants and contracts revenues			-
Direct costs recovered	466,504		466,504
Facilities and administrative costs recovered	168,737		168,737
Patient services, net	1,381,149		1,381,149
Auxiliary enterprises - sales and services	126,182		126,182
Educational activities - sales and services	195,738		195,738
Affiliated hospital revenues	125,321		125,321
Other revenue	42,943	15	42,958
Net assets released from restrictions	132,292	(132,292)	-
Total Revenues and other support	<u>3,575,347</u>	<u>(30,813)</u>	<u>3,544,534</u>
Expenses:			
Compensation expense	2,041,168		2,041,168
Supplies, services, and other	1,060,079		1,060,079
Depreciation expense	188,858		188,858
Interest expense	65,629		65,629
Total expenses	<u>3,355,734</u>	<u>-</u>	<u>3,355,734</u>
Net operating results	<u>219,613</u>	<u>(30,813)</u>	<u>188,800</u>
Non-operating revenues and (expenses):			
Investment returns net of endowment spending	139,305	128,890	268,195
Permanently restricted gifts		120,914	120,914
Other non-operating	(36,966)	14,021	(22,945)
Non-operating, net	<u>102,339</u>	<u>263,825</u>	<u>366,164</u>
Change in net assets	321,952	233,012	554,964
Net Assets, Beginning of the Year	<u>5,154,934</u>	<u>5,339,034</u>	<u>10,493,968</u>
Net Assets, End of the Year	<u>\$ 5,476,886</u>	<u>\$ 5,572,046</u>	<u>\$ 11,048,932</u>

The accompanying notes are an integral part of these consolidated financial statements.

Washington University

Consolidated Statements of Cash Flows

Years Ended June 30, 2020 and 2019

(thousands of dollars)

	2020	2019
Cash flows from operating activities		
Change in net assets	\$ 719,373	\$ 554,964
Adjustments to reconcile change in net assets to cash provided by operating activities		
Realized and unrealized net gains on investments	(899,464)	(644,999)
Depreciation expense	201,973	188,858
Permanently restricted gifts	(80,184)	(120,914)
Investments received as gifts - not permanently restricted	(11,070)	(9,780)
Proceeds from sales of investments received as gifts	11,070	9,780
Debt extinguishment costs	9,635	-
Other non-cash adjustments	59,127	(27,225)
Changes in assets and liabilities		
Accounts and notes receivable, net	47,113	(91,692)
Pledges receivable, net	(49,691)	52,044
Accounts payable and accrued expenses	(6,907)	88,511
Deposits and advances	3,442	(24,860)
Other assets and liabilities	15,542	6,300
Net cash provided/(used) by operating activities	<u>19,959</u>	<u>(19,013)</u>
Cash flows from investing activities		
Proceeds from sales and maturities of investments	5,805,217	6,827,007
Purchases of investments	(5,925,802)	(6,553,046)
Purchases of fixed assets	(397,220)	(379,697)
Student loans disbursed	(15,516)	(14,637)
Student loan payments received	20,459	21,901
Other	45	4
Net cash used in investing activities	<u>(512,817)</u>	<u>(98,468)</u>
Cash flows from financing activities		
Principal payments of debt	(150,436)	(22,099)
Proceeds from long-term debt issuance	509,037	55,298
Contributions restricted for long-term investment	55,465	79,769
Proceeds from sales of investments received as gifts	19,152	39,338
Debt extinguishment costs	(9,635)	-
Other	(14,579)	(1,250)
Net cash provided by financing activities	<u>409,004</u>	<u>151,056</u>
Net (decrease)/increase in cash	(83,854)	33,575
Cash and cash equivalents		
Beginning of year	<u>400,100</u>	<u>366,525</u>
End of year	<u>\$ 316,246</u>	<u>\$ 400,100</u>
Supplemental data		
Interest paid in cash	\$ 66,566	\$ 64,212
Noncash activities		
Contributions of securities and other noncash assets	36,211	49,137
Net change in accounts payable for fixed assets	(5,094)	8,501
Net change in accounts receivable for investments	16,678	(37,185)
Net change in accounts payable for investments	(114,118)	122,649

The accompanying notes are an integral part of these consolidated financial statements.

Washington University

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(All amounts in thousands of dollars)

1. Summary of Significant Accounting Policies

Organization

Washington University in St. Louis (the “university”), is an institution of higher education that, in furtherance of its role as a charitable and educational institution, engages in various activities, including instruction, research and provision of medical care.

Basis of Presentation and Use of Estimates

The consolidated financial statements have been prepared on the accrual basis of accounting. The consolidated financial statements are consolidated to include the accounts of the university and its affiliates. Significant consolidated affiliates include The Barnard Free Skin and Cancer Hospital, Parallel Properties LLC including its affiliates, Washington University Clinical Associates, LLC and associated physician practices, and Washington University Physicians in Illinois, Inc.

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include, but are not limited to, the estimated useful lives of buildings and equipment, the fair value of certain investments (see footnote 2), the degree of precision in calculation of self-insurance reserves and adequacy of allowances for doubtful accounts. Actual results could differ from those estimates.

Net Assets

Resources are recorded based on the absence or existence of donor-imposed restrictions. Descriptions of the net asset categories follow:

- Net assets without donor restrictions are free of donor-imposed restrictions. Board-designated endowment funds are also included within net assets without donor restrictions.
- Net assets with donor restrictions represent net assets that consist of gifts and related earnings that are subject to donor-imposed restrictions or legal stipulations that have not yet been met by actions of the university and/or passage of time as well as gifts and trusts which, by donor restriction, are required to be held in perpetuity. Net assets required to be held in perpetuity at June 30, 2020 and 2019, are \$2,365,401 and \$2,283,398, respectively.

Revenues from sources other than contributions and investment returns are reported as increases in net assets without donor restrictions. Contributions are reported as increases in the appropriate category of net assets, except that contributions which impose donor restrictions that are met in the same fiscal year they are received are included in revenues without donor restrictions. Gains and investment income that are limited to specific uses by donor-imposed restrictions are reported as increases in net assets without donor restrictions if the restrictions are met in the same reporting period as the gains and income are recognized, except for gains and investment income earned by investment of donor-restricted endowments. Such amounts remain in net assets with donor restrictions until appropriated for expenditure. When a donor restriction expires due to the passage of time or the university’s fulfillment of donor stipulated purpose, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the Consolidated Statements of Activities as net assets released from restrictions. Donor restricted gifts that are to be held in perpetuity are reported in the non-operating section of the Consolidated

Washington University
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

(All amounts in thousands of dollars)

Statements of Activities. Gifts of long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported as restricted support. Absent explicit donor stipulations about how long those long-lived assets must be maintained, the university reports expirations of donor restrictions when the donated or acquired long-lived assets are placed in service. Expenses are reported as decreases in net assets without donor restrictions.

The university's net assets as of June 30, 2020 consist of the following:

	Without donor restrictions	With donor restrictions	Total
Donor-restricted endowment funds		\$ 5,103,500	\$ 5,103,500
Board-designated endowment funds	\$ 3,085,820	299,976	3,385,796
Investment in plant, net	762,165		762,165
Pledges		441,909	441,909
Other donor-restricted		37,192	37,192
Operating and other reserves	<u>2,037,743</u>		<u>2,037,743</u>
	<u>\$ 5,885,728</u>	<u>\$ 5,882,577</u>	<u>\$ 11,768,305</u>

The university's net assets as of June 30, 2019 consist of the following:

	Without donor restrictions	With donor restrictions	Total
Donor-restricted endowment funds		\$ 4,891,626	\$ 4,891,626
Board-designated endowment funds	\$ 2,845,594	271,705	3,117,299
Investment in plant, net	711,525		711,525
Pledges		389,944	389,944
Other donor-restricted		18,771	18,771
Operating and other reserves	<u>1,919,767</u>		<u>1,919,767</u>
	<u>\$ 5,476,886</u>	<u>\$ 5,572,046</u>	<u>\$ 11,048,932</u>

Investments

Investment gains (losses) in excess of endowment spending distribution and the unrealized appreciation (depreciation) on investments are reported in the non-operating section of the Consolidated Statements of Activities. Investments acquired by gift or bequest are initially recorded at market or appraised value at the date so acquired.

At June 30, 2020 and 2019, investments include \$274,683 and \$39,185, respectively, purchased with unexpended proceeds from the Series 2017 A Missouri Health and Educational Facilities Authority (MOHEFA) revenue bonds issued July 6, 2017 and the Series 2020A taxable revenue bonds issued April 3, 2020. These 2017A MOHEFA funds may only be expended for specific construction project costs and costs of issuance. The 2020A bond funds may be utilized for a broader range of projects.

Washington University
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

(All amounts in thousands of dollars)

Fixed Assets

Fixed assets are stated at cost or at fair market values if received as a gift, less accumulated depreciation, computed on a straight-line basis over the estimated useful lives of the assets. Fixed assets include equipment and other assets acquired through sponsored programs during which title is retained by the resource provider. It is probable the university will be permitted to keep the assets when the program terminates. The cost and accumulated depreciation of fixed assets are removed from the records at the time of disposal. Fixed assets by classification at June 30, 2020 and 2019 consist of the following:

	<u>2020</u>	<u>2019</u>
Construction in progress	\$ 311,806	\$ 327,827 *
Land and improvements to land	178,356	160,860
Buildings	4,502,505	4,198,698 *
Equipment	<u>619,921</u>	<u>573,804</u>
Total cost	5,612,588	5,261,189
Accumulated depreciation	<u>(2,709,765)</u>	<u>(2,524,761)</u>
Total fixed assets, net	<u>\$ 2,902,823</u>	<u>\$ 2,736,428</u>

* Certain prior year amounts have been reclassified to conform to the current year's presentation. The reclassifications had no impact on the total net assets, total change in net assets, the statement of financial position, or the statement of cash flows.

Collections

In addition to the Mildred Lane Kemper Art Museum, the university archives rare book collections, works of art, literary works, historical treasures and artifacts. These collections are protected and preserved for public exhibition, education, research and the furtherance of public service. They are neither disposed of for financial gain nor encumbered in any manner. Accordingly, such collections are not recognized or capitalized for financial statement purposes.

Financing Receivables

Financing receivables are principally loans made to students or their parents utilizing gifts, endowment payout, and university resources designated for that purpose and from funds provided by the United States government under the Federal Perkins and Health Professional Student Loan programs. Loan funds are reported at estimated realizable value, as it is not practical to determine the fair value of loan fund receivables, which include a large component of federally sponsored student loans. Federally sponsored student loans have significant government restrictions as to marketability, interest rates, and repayment terms. Federal funds are ultimately refundable to the government and are recognized as a liability in the Consolidated Statements of Financial Position (see footnote 6).

The university's loan portfolio includes over 6,800 individual loans and is geographically diverse. Loans are considered past due if the minimum payment is not received within thirty-one days past the due date. At June 30, 2020 and 2019, respectively 94% and 90% of the parent loans and 74% and 74% of the institutional student loans were considered current. Income earned on financing receivables is recorded on an accrual basis.

Washington University

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(All amounts in thousands of dollars)

Deferred Revenue and Contract Liabilities

Deferred revenue is recognized on an accrual basis when payments for services are received in advance of performance by the university. The principle components of deferred revenue are clinical trial receipts, grants and contracts, and prepaid tuition and housing.

Revenue Recognition

On July 1, 2018, the university adopted the Financial Accounting Standards Board, Accounting Standards Update 2014-09, *Revenue from Contracts with Customers* (ASC 606). Prior to the adoption of ASC 606, the University recognized revenue under ASC 605, which focused on transaction specific guidance for revenue recognition. ASC 606 affects all contracts entered into with customers that result in a transfer of goods or services or a transfer of non-financial assets. The core principle of the standard is for organizations to recognize revenue in a way that depicts the transfer of goods or services to customers in amounts that reflect the consideration or payment to which the organization expects to be entitled. The university adopted ASC 606 using the modified retrospective method, whereby the cumulative effect of applying the standard is recognized in net assets on the date of adoption. The university elected to apply the new standard only to contracts not completed at the adoption date. Except for Sponsored Research Contracts within Grants and Contracts, Educational Activities Sales and Services and Clinical Trials, substantially all contracts are less than 12 months in duration and the university has elected to expense contract costs as incurred and to not adjust the transaction price for any significant financing component.

The university recorded revenue from contracts with customers during fiscal 2019 in the major service categories presented in the table below. The total amounts reported in Grants and Contracts on the Statement of Activities includes contribution income which is not included in the Sponsored Research Contracts within Grants and Contracts in the table below.

When using the modified retrospective approach, comparative prior period information continues to be accounted for under the accounting standards in effect for the period presented. ASC 606 changed the pattern of revenue recognition for some contracts with customers. Implicit price concessions are now recognized when revenue is first recognized for both tuition and patient services. Clinical trial revenue is adjusted to be consistent with the input method described below.

The effect by line item in the 2019 Statement of Activities of this change is presented in the table below.

	Under ASC 605	Effect	Under ASC 606
Tuition and fees, net of scholarship	\$ 441,942	\$ (27)	\$ 441,915
Sponsored research contracts within grants and contracts	31,577	-	31,577
Patient services	1,492,702	(111,553)	1,381,149
Auxiliary enterprises - sales and services	126,182	-	126,182
Educational activities - sales and services			
Clinical trials revenue	82,337	2,853	85,190
Other activities	110,548	-	110,548
Affiliated hospital revenue	125,321	-	125,321
Supplies, services, and other expense	1,171,659	(111,580)	1,060,079

Washington University
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

(All amounts in thousands of dollars)

Tuition and Fees

Tuition and fee revenue, net of scholarships and other implicit price concessions, is recognized over-time using the output method of measuring progress in the fiscal year in which the educational programs are conducted. Students are invoiced at the commencement of each academic period. Payment is due when invoiced. The performance obligation, delivery of educational services, is satisfied as services are rendered. If delivery of the performance obligation is not complete as of fiscal year-end, a contractual liability is recorded. The deferred contract liability at June 30, 2020 and 2019 was \$45,962 and \$49,992, respectively, and is reported as deferred revenue and contract liabilities on the Statement of Financial Position.

Demonstrated financial need is the major criteria for undergraduate students to receive financial aid. Graduate students often receive tuition support in connection with research assistant, teaching assistant and fellowship appointments. Total financial aid granted to students by the university, including aid provided to employees and their dependents, for the years ended June 30, 2020 and 2019, respectively, was \$413,029 and \$387,069. The table below identifies student aid by type. Scholarships are reported net against tuition in the Consolidated Statements of Activities. Other amounts are reported as expenses.

	<u>2020</u>	<u>2019</u>
Scholarships from unrestricted sources	\$ 221,068	\$ 202,587
Scholarship support from gifts, endowment and other restricted sources	74,081	68,195
Total scholarships	<u>295,149</u>	<u>270,782</u>
Employee and dependent tuition benefits	38,446	37,531
Stipends	77,326	76,443
Work study	2,108	2,313
Total	<u>\$ 413,029</u>	<u>\$ 387,069</u>

Gifts

Gifts, including unconditional promises to give, are recognized as revenues in the period the gift or promise is received. Gifts received for permanent endowments or perpetual trusts are reported as non-operating revenues. Gifts of assets other than cash are recorded at their estimated fair value at the date of gift and, unless instructed otherwise by the donor, are liquidated upon receipt or as soon as practical thereafter.

Conditional gifts and promises to give are not recognized until the conditions on which they depend are substantially met. Gifts, in the form of unconditional promises to give, to be received after one year are discounted at credit-adjusted tax exempt borrowing rates in accordance with fair value accounting. Pledges outstanding are discounted with rates ranging from 0.57% to 2.04%. Amortization of the discount is recorded as gift revenue. The university has received gifts which are recorded as gift revenue in the period the gift was made but are payable over a specified payment schedule of up to 10 years or more. During the gift payment term, the university is exposed to credit risk for the entity or individual that has made the gift. An allowance is made for uncollectible unconditional promises to give based upon management's judgment, past collections experience and other relevant factors.

Washington University
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

(All amounts in thousands of dollars)

A summary of pledges receivable is as follows:

	<u>2020</u>	<u>2019</u>
In one year or less	\$ 165,399	\$ 122,226
Between two and five years	153,459	172,661
Over five years	<u>144,145</u>	<u>116,732</u>
	463,003	411,619
Less:		
Discount	(12,540)	(16,414)
Allowance for uncollectible amounts	<u>(8,554)</u>	<u>(5,261)</u>
Total	<u>\$ 441,909</u>	<u>\$ 389,944</u>

Grants and Contracts

The university receives grant and contract revenue from governmental and private sources. Revenue associated with the direct costs of sponsored programs is generally recognized as the related costs are incurred. At contract inception, the university determines whether the goods or services to be provided are to be accounted for as a single performance obligation or as multiple performance obligations. If multiple performance obligations are identified, the university generally uses the cost plus a margin approach to determine the relative standalone selling price of each performance obligation. Revenue from these contracts is earned over-time. Invoicing of the customer, if required, will generally be in accordance with terms of the contract with payment due when invoiced. Generally, the time between the receipt of payment and the transfer of goods and service under these contracts is less than one year.

The university records revenue without donor restrictions upon its recovery of direct and indirect costs applicable to those sponsored programs that provide for the full or partial reimbursement of such costs. Most grants awarded to the university by government agencies are conditional contributions. The principle condition attached to these awards is that the university must incur costs in accordance with the Office of Management and Budget's uniform guidance before costs can be reimbursed. Total amounts promised under these grants for which conditions have not yet been fulfilled are approximately \$879,544 and \$807,235 at June 30, 2020 and June 30, 2019, respectively. The recovery of indirect costs, also referred to as facilities and administrative costs is based on negotiated rates and represents recoveries of facilities and administrative costs incurred under grants and contracts agreements. Recovery of facilities and administrative costs of Federally sponsored programs is at rates negotiated with the Department of Health and Human Services.

In some cases, the sponsor will prepay amounts in anticipation of costs to be incurred. In those cases, amounts received in excess of costs incurred are recorded as contract liabilities. The contract liabilities amounts at June 30, 2020 and 2019 are \$7,392 and \$13,287, respectively.

Patient Services Revenue

Net patient service revenue is reported at the amount that reflects the consideration to which the university expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payers (including health insurers and government programs), and others. Generally, the university bills the patient and third-party payers several days after the services are performed. Revenue is recognized as performance obligations are satisfied.

Washington University

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(All amounts in thousands of dollars)

Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected or actual charges which provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation.

Because the majority of its performance obligations relate to contracts with a duration of less than one year, the university has elected to apply the practical expedient provided in FASB ASC 606-10-50-14a, and therefore is not required to disclose the aggregate amounts of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period.

Generally patients who are covered by third-party payers are responsible for related deductibles and coinsurance, which vary in amount. The university also provides services to uninsured patients. The transaction price for both uninsured patients, as well as insured patients with deductibles and coinsurance, is estimated based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts and implicit price concessions. The university determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. The university determines its estimate of implicit price concessions based on historical collection experience with these classes of patients using a portfolio approach as a practical expedient. The portfolio approach is being used as there are a large volume of similar contracts with similar classes of customers. Management's judgment to group the contracts by portfolio is based on the payment behavior expected in each portfolio category. The effect of applying a portfolio approach to a group of contracts would not differ materially from considering each contract separately. Contractual adjustments to patient service revenue were \$1.84 billion and \$1.79 billion for the years ended June 30, 2020 and 2019, respectively.

The university has elected the practical expedient allowed under FASB ASC 606-10-32-18 and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. In certain instances, the university may enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract. The university reported net accounts receivable for patient services of \$144,755 and \$168,877, at June 30, 2020 and 2019, respectively.

Auxiliary Enterprises – Sales and Services

Auxiliary enterprises sales and services revenue is primarily earned over-time utilizing the output method of measuring progress. Auxiliary enterprise sales and services contracts will generally constitute a single performance obligation as there is a single promise. This revenue is composed primarily of on and off campus housing charges, dining services, and parking and transportation fees with separate contracts for each type of service. Housing, dining services and parking fees are invoiced to undergraduate students at the beginning of each academic period. Payment is due upon invoice issuance. Graduate students and undergraduates who live off campus sign rental agreements providing for monthly rent payments. Each contract for services in this category has a duration of one year or less. A contract liability is recorded for the delivery of performance obligations that is not completed prior to the fiscal year end. The contract liabilities at June 30,

Washington University

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(All amounts in thousands of dollars)

2020 and 2019 are \$9,549 and \$10,034, respectively, and are reported as deferred revenue and contract liabilities on the Statement of Financial Position.

Educational Activities – Sales and Services

Clinical trial revenue is earned over-time as the university provides services. The transaction price is negotiated with the customer and is usually based on standard rates for clinical services and the expected cost to complete the contract. Payment terms under these contracts vary but generally provide for the right to invoice the customer as work progresses, either based on units performed or the achievement of billing milestones. The university has determined that an input method using costs incurred as a basis to estimate revenue earned best depicts the pattern of transfer of control to the customer. In those limited cases where prepayments are significant, revenue is deferred until earned and a contract liability is recorded. The contract liabilities at June 30, 2020 and 2019 are \$56,325 and \$40,954, respectively, and are reported as deferred revenue and contract liabilities on the Statement of Financial Position.

Contracts in other educational sales and services cover a broad range of activities including physician services to affiliated and unaffiliated hospitals, executive education program fees and royalties. Revenue from the contracts in this category is earned over time as services are rendered. The measure of progress varies according to the nature of the services provided. Invoicing to customers is performed in the cadence required under the contracts and amounts invoiced generally are considered due upon receipt. Accruals for services provided but not yet invoiced are recorded at year end. Amounts receivable under service contracts are \$72,635 and \$85,497 at June 30, 2020 and 2019, respectively. Fees for executive education programs are often received in advance of the program and represent a contract liability. Such amounts are reported as deferred revenue and contract liabilities in the Statement of Financial Position.

Affiliated Hospital Revenues

Affiliated hospital revenue is earned over-time as the various services are provided as an integrated performance obligation as more fully described in footnote 12. The measure of progress towards completion of those obligations is based on the day-to-day operations of the University's School of Medicine and the affiliated hospitals. Payments are received under the agreement semiannually. Amounts receivable under the agreement are \$68,577 and \$62,633 at June 30, 2020 and 2019 respectively.

Operating Results

The university's measure of operations as presented in the Consolidated Statements of Activities includes income from tuition and fees, grants and contracts, medical services, contributions for operating programs, the endowment spending distribution and other revenues. Operating expenses are reported on the Consolidated Statements of Activities as incurred for employee compensation, depreciation, interest and supplies, services and other. Operating results exclude investment gains (losses) except for the portion of gains utilized for the endowment spending distribution, contributions to be held in perpetuity, and other non-operating amounts.

Split-Interest Agreements

The university's split-interest agreements with donors consist primarily of charitable gift annuities and irrevocable charitable remainder trusts for which the university serves as trustee. Assets are invested and payments are made to donors and/or other beneficiaries in accordance with the respective agreements. Contribution revenues for charitable gift annuities and charitable remainder trusts are recognized after recording liabilities for the present value of the estimated

Washington University

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(All amounts in thousands of dollars)

future payments to be made to the respective donors and/or other beneficiaries. The discount rate used is a credit-adjusted rate in existence at the date of the gift. The rates used range from 1.37% to 2.31% for 2020 and 1.94% to 3.27% for fiscal year 2019. Annually, the university records the change in value of split-interest agreements by recording at fair value the assets that are associated with each trust and recalculating the liability for the present value of the estimated future payments to be made to the donors and/or other beneficiaries. For the years ending June 30, 2020 and 2019, the change in fair value was a decrease of \$2,964 and an increase of \$73, respectively. As of June 30, 2020 and 2019, the university's liability under charitable gift annuities was \$19,710 and \$20,077, respectively.

Cash and Cash Equivalents

The university considers cash on hand and in banks and all highly liquid financial instruments with an original maturity of 90 days or less, except those amounts assigned to and invested by its investment managers, which amounts are classified as investments, to be cash and cash equivalents.

Income Taxes

The university is exempt from federal income taxes under Section 501 (c)(3) of the Internal Revenue Code except to the extent the university has unrelated business income, or consolidated for-profit affiliates incur taxes. The Tax Cuts and Jobs Act (the "Act") was enacted on December 22, 2017. The Act impacts the university in several ways, including new excise taxes on executive compensation and net investment income, increases to unrelated business taxable income (UBTI) , changes to the net operating loss rules, repeal of the alternative minimum tax (AMT), and the computation of UBTI separately for each unrelated trade or business. Further, the Act reduces the U.S. federal corporate tax rate and federal corporate unrelated business income tax rate from 35% to 21%. The overall impact of the Act remains uncertain and the full impact of the Act will not be known until further regulatory guidance is provided to assist the university with calculating income and excise tax liabilities. The university continues to evaluate the impact of tax reform on the organization.

As of June 30, 2020, the university has made a reasonable estimate of the determinable effects of the enactment of the Act, including the effect of an amendment to the Act passed during fiscal year 2020 to exclude certain fringe benefits previously deemed to be taxable income, on existing deferred tax balances. These amounts are provisional, subject to change and not material to the university's consolidated financial statements. Management believes the university has no uncertain tax positions that result in material unrecognized tax expense/benefits.

Effects of the Pandemic

The outbreak of COVID -19 has caused domestic and global disruption in operations for institutions of higher education. The impact (i) may materially affect the cost of operations and (ii) may materially affect financial markets and consequently the returns on and value of the university's investments. Other adverse consequences of COVID-19 or any other similar outbreaks in the future may include, but are not limited to, decline in enrollment, decline in demand for university housing and decline in demand for university programs that involve travel or have international connections. The full impact of COVID-19 or any other similar outbreaks in the future and the scope of any adverse impact on the university's finances and operations cannot be fully determined at this time.

Washington University

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(All amounts in thousands of dollars)

The University received funding from the federal Coronavirus Aid, Relief and Economic Security (“CARES”) Act Provider Relief Fund, recognized as a portion of “Other Revenues” in the Consolidated Statement of Activities as of June 30, 2020, to be retained and used only for reimbursement of eligible expenses and lost revenues in accordance with laws, regulations and guidance issued by the U.S. Department of Health and Human Services. There is a reasonable possibility that amounts recognized as a portion of Other Revenue may change in future periods based on future HHS interpretations and/or as guidance issued by HHS related to the funding continues to evolve.

Adopted Accounting Pronouncements

During fiscal 2016, the FASB issued ASU 2016-02, *Leases*. The ASU requires lessees to recognize in the Statements of Financial Position for leases with a term of greater than one year, a liability to make lease payments and a right-of-use asset representing its right to use the asset for the lease term. Generally, lease payments will be recognized as interest expense and as a reduction of the liability. The asset will be amortized over the life of the lease. Accounting by a lessor will be largely unchanged from that required by current generally accepted accounting principles. In June 2020, the FASB issued ASU 2020-05, *Effective Dates for Certain Entities*, which allows the university to defer for one year the adoption of ASU 2016-02 from fiscal year 2020 to fiscal year 2021. The university elected to defer adoption and is evaluating the impact of ASU 2016-02 to the consolidated financial statements.

In August and November 2016, the FASB issued two standards on the presentation of certain items in the statement of cash flows. ASU 2016-15, *Classification of Certain Cash Receipts and Cash Payments*, provides guidance on the appropriate classification of certain cash flow items as operating, investing, and financing activities, including prepayments on debt and debt extinguishment costs. ASU 2016-18, *Restricted Cash*, requires the statement of cash flows to present the changes in all cash and cash equivalents, including restricted cash, and provide additional disclosures regarding the nature of restrictions on cash. The university adopted these standards during fiscal year 2020 with no material effect on the Statements of Cash Flow.

2. Fair Value

The university follows FASB guidance for fair value measurements. This guidance defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

The FASB guidance establishes a hierarchy of valuation inputs based on the extent to which the inputs are observable in the marketplace. Observable inputs reflect market data obtained from sources independent of the university and unobservable inputs reflect the university’s assumptions about how market participants would value an asset or liability based on the best information available. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value.

Washington University

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(All amounts in thousands of dollars)

The following describes the hierarchy of inputs used to measure fair value and the primary valuation methodologies used by the university for financial instruments measured at fair value on a recurring basis. The three levels of inputs are as follows:

- Level 1 Quoted prices in active markets for identical assets or liabilities, such as exchange traded equity securities.
- Level 2 Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the same term of the assets or liabilities. Examples of Level 2 include U.S. Treasury securities and corporate bonds.
- Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The following table presents the financial instruments carried at fair value as of June 30, 2020, on the Consolidated Statements of Financial Position by caption and by the valuation hierarchy defined above. Amounts measured at net asset value are reported using the practical expedient under ASC topic 820 and excluded from the fair value hierarchy. Included as Level 2 fixed income are U.S. Treasury securities of approximately \$656,460.

	Quoted Prices in Active Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Measured at Net Asset Value	Balance June 30, 2020
Investments					
Public equity					
Domestic	\$ 134,100	\$ 27		\$ 938,834	\$ 1,072,961
International	96,173			2,098,450	2,194,623
Fixed income - Nominal		820,224			820,224
Absolute return				1,015,840	1,015,840
Private capital			\$ 158,996	4,224,579	4,383,575
Short-term investments	137,437	3,824			141,261
Real assets			2,128	534,686	536,814
Other investments	314,574	(650)	69,724	31,241	414,889
Total investments at fair value	682,284	823,425	230,848	8,843,630	10,580,187
Investments not reported at fair value					
Affiliates - Equity basis	-	-	-	-	33,561
Accrued investment income	-	-	-	-	2,778
Total investments	\$ 682,284	\$ 823,425	\$ 230,848	\$ 8,843,630	\$ 10,616,526

Washington University

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(All amounts in thousands of dollars)

The following table presents the financial instruments carried at fair value as of June 30, 2019, by caption on the Consolidated Statements of Financial Position and by the valuation hierarchy defined above. Included as Level 2 fixed income are U.S. Treasury securities of approximately \$714,396.

	Quoted Prices in Active Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Measured at Net Asset Value	Balance June 30, 2019
Investments					
Public equity					
Domestic	\$ 5,505	\$ 27		\$ 1,250,989	\$ 1,256,521
International	21,344	-		2,039,837	2,061,181
Fixed income - Nominal		778,146		-	778,146
Absolute return				1,125,310	1,125,310
Private capital			\$ 130,923	3,208,676	3,339,599
Short-term investments	345,121	12,237			357,358
Real assets	-	-	110,600	473,025	583,625
Other investments	80,696	(1,101)	70,183	34,485	184,263
Total investments at fair value	452,666	789,309	311,706	8,132,322	9,686,003
Investments not reported at fair value					
Affiliates - Equity basis	-	-	-	-	32,443
Accrued investment income	-	-	-	-	5,490
Total investments	\$ 452,666	\$ 789,309	\$ 311,706	\$ 8,132,322	\$ 9,723,936

Beneficial interests in perpetual trusts held by third parties are valued at the present value of the future distributions expected to be received over the term of the agreement.

Following is a description of the university's valuation methodologies for assets and liabilities measured at fair value. The methods described below may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the university believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

Fair value for Level 1 is based upon quoted prices in active markets that the university has the ability to access for identical assets and liabilities. Market price data is generally obtained from exchange or dealer markets. The university does not adjust the quoted price for such assets and liabilities.

Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Inputs are obtained from various sources including market participants, dealers, and brokers.

Fair value for Level 3 is based on valuation techniques that use significant inputs that are unobservable as they trade infrequently or not at all. Trustees determine the valuation for beneficial interest trusts and split-interest agreements. Strategic real estate is valued at historical cost and is evaluated annually for impairment.

Washington University
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

(All amounts in thousands of dollars)

Investments measured at net asset value primarily consist of the university's ownership in alternative investments (principally limited partnership interests in absolute return, private capital investments, real assets, and other similar funds). The fair values (Net Asset Value ("NAV") or partner's capital per share) of the securities held by limited partnerships that do not have readily determinable fair values are determined by the respective general partners and are based on appraisals or other estimates that require varying degrees of judgment. If no public market exists for the investments, the fair value is determined by the general partners taking into consideration significant unobservable inputs including, among other things, the cost of the investments, prices of recent significant placements of investments of the same issuer, and subsequent developments concerning the companies to which the investments relate. Excluding the cost of the investment, significant increases or decreases in the remainder of those inputs could result in a significantly higher or lower fair value measurement. The university has performed due diligence with respect to these investments to ensure NAV or partner's capital per share is an appropriate measure of fair value as of June 30. NAVs are calculated by the investees in a manner consistent with generally accepted accounting principles for investment companies.

Significant terms of agreements with external investment managers or funds by major classes of investments are provided in the following tables.

The following table summarizes the significant terms of the agreements with external investment managers or funds by major category at June 30, 2020:

Investments	Unfunded Commitment (1)	Remaining Life (2)	Redemption Terms	Redemption Restrictions
Public equities	\$ 1,805	2 Years - No Limit	Daily to annually, with 1 day-1 year notice	Lock-up provision periods range from 0 to 5 years. Certain investments include side pockets subject to external manager discretion.
Fixed income and short-term investments	-	No Limit	Daily, 1-2 days notice	No lock-up provision periods
Absolute return	-	1 Year - No Limit	Quarterly to semi-annually with 45 – 180 days notice	Lock-up provision periods range from 0 to 3 years. Certain investments include side pockets subject to external manager discretion.
Private capital	1,700,420	0 - 29 Years	Not eligible for redemption	Not redeemable
Real assets	335,813	0 - 11 Years	Not eligible for redemption	Not redeemable
Total	\$ 2,038,038			

Washington University
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

(All amounts in thousands of dollars)

Footnote (1): Includes \$28 million nonbinding unfunded commitments. The university is obligated under certain agreements to fund capital calls periodically up to specified commitment amounts. Such commitments are expected to be called over the life of the agreement and are not expected to be fully funded in the subsequent year.

Footnote (2): For private equities and real assets, assuming all extension options under the agreements are exercised and approved except for funds with no fund life end date or unlimited extension.

The following table summarizes the significant terms of the agreements with external investment managers or funds by major category at June 30, 2019:

Investments	Unfunded Commitment (1)	Remaining Life (2)	Redemption Terms	Redemption Restrictions
Public equities	\$ 72,067	4 Years - No Limit	Daily to annually, with 1 day-1 year notice	Lock-up provision periods range from 0 to 5 years. Certain investments include side pockets subject to external manager discretion.
Fixed income and short-term investments	-	No Limit	Daily, 1-2 days notice	No lock-up provision periods
Absolute return	50,000	No Limit	Monthly to annually, with 30 -180 days notice	Lock-up provision periods range from 0 to 3 years. Certain investments include side pockets subject to external manager discretion.
Private capital	1,716,831	0 - 23 Years	Not eligible for redemption	Not redeemable
Real assets	446,607	0 - 12 Years	Not eligible for redemption	Not redeemable
Total	\$ 2,285,505			

Footnote (1): The university is obligated under certain agreements to fund capital calls periodically up to specified commitment amounts. Such commitments are expected to be called over the life of the agreement and are not expected to be fully funded in the subsequent year.

Footnote (2): Assuming all extension options under the agreements are exercised and approved.

Public Equities

Public equities include investments in publicly-traded securities in domestic, developed international, emerging, and frontier markets. The majority of assets are held in pooled comingled funds which are valued at NAV as described above. Investments held in custody accounts are valued at quoted market price in accordance with Level 1 and Level 2 valuation techniques as described above.

Washington University

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(All amounts in thousands of dollars)

Fixed Income and Short-Term Investments

Investments in this class include domestic and international nominal fixed income instruments. Fixed income investments are held principally as liquid vehicles for operating needs and as a source of diversification. A significant component of non-endowment fixed income investments is held in highly liquid funds. The valuation of these funds is determined using a market approach in accordance with the techniques for Level 2 as described above.

Absolute Return

Investments in absolute return are typically held in commingled funds that employ various uncorrelated investment strategies including but not limited to equity hedged and event driven. These funds are valued at net asset value as described above.

Private Capital

Investments in private capital strategies are made in targeted categories including growth equity, venture capital, distressed credit, and corporate finance. Redemptions of such funds are not permitted and distributions are received as underlying investments are liquidated. These funds are primarily valued at net asset value as described above.

Real Assets

Investments in the real assets class are made in targeted categories. The majority of these assets are held in non-redeemable fund structures that invest primarily in real estate and natural resources. These funds are primarily valued at net asset value as described above.

The following tables roll forward the Statements of Financial Position amounts for financial instruments classified by the university within Level 3 of the fair value hierarchy defined above for the years ended June 30, 2020 and 2019.

	Balance June 30, 2019	Net Realized and Unrealized Gains (Losses)	Purchases, Sales and Settlements Net	Transfers in/(out) of Level 3, net	Balance June 30, 2020
Investments (by strategy)					
Private capital	\$ 130,923	\$ (1,296)	\$ 31,425	\$ (2,056)	\$ 158,996
Real assets	110,600	363	(108,835)	-	2,128
Other investments	70,183	643	102	(1,204)	69,724
Total	<u>\$ 311,706</u>	<u>\$ (290)</u>	<u>\$ (77,308)</u>	<u>\$ (3,260)</u>	<u>\$ 230,848</u>

The amount of realized and unrealized gains (losses) for Level 3 investments for the period included in net assets attributable to the change in unrealized gains or losses relating to assets still held at June 30, 2020, reported as investment returns net of endowment spending in the Statements of Activities by type of investment is:

Private capital	\$ (129)
Real assets	3,973
Other investments	<u>(341)</u>
Total	<u>\$ 3,503</u>

Washington University
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

(All amounts in thousands of dollars)

	Balance June 30, 2018	Net Realized and Unrealized Gains (Losses)	Purchases, Sales and Settlements Net	Transfers in/(out) of Level 3, net	Balance June 30, 2019
Investments (by strategy)					
Private capital	\$ 118,087	\$ 27,647	\$ 3,907	\$ (18,718)	\$ 130,923
Real assets	18,833	4,894	31,288	55,585	110,600
Other investments	67,688	2,308	1,801	(1,614)	70,183
Total	<u>\$ 204,608</u>	<u>\$ 34,849</u>	<u>\$ 36,996</u>	<u>\$ 35,253</u>	<u>\$ 311,706</u>

It is probable that all of the real assets reported as Level 3 above will be sold at an amount different from the net asset value of the university's ownership interest in partners' capital. The fair value of these investments has been estimated at the expected selling price of these investments based on sale negotiations in process at June 30, 2019.

The amount of realized and unrealized gains (losses) for Level 3 investments for the period included in net assets attributable to the change in unrealized gains or losses relating to assets still held at June 30, 2019, reported as investment returns net of endowment spending in the Statements of Activities by type of investment is:

Private capital	\$ 29,126
Real assets	(1,436)
Other investments	<u>1,060</u>
Total	<u>\$ 28,750</u>

3. Investment Return

The following summarizes the return on investments. Investment income represents earnings on non-endowed funds. Return on investments is presented net of investment management fees. Certain investments, including some but not all of those in the absolute return and private capital categories, report investment returns net of fees.

	2020	2019
Investment income	<u>\$ 21,172</u>	<u>\$ 27,482</u>
Pooled endowment dividends and interest income, net of investment management fees	(59,117)	(35,492)
Pooled endowment distribution in excess of income	<u>420,989</u>	<u>376,804</u>
Pooled endowment spending distribution	<u>361,872</u>	<u>341,312</u>
Investment gains, net	899,464	644,999
Gains distributed as endowment distribution	<u>(420,989)</u>	<u>(376,804)</u>
Investment gains net of endowment spending distribution	<u>478,475</u>	<u>268,195</u>
Net investment return	<u>\$ 861,519</u>	<u>\$ 636,989</u>

Washington University
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

(All amounts in thousands of dollars)

4. Endowment

The state of Missouri has adopted legislation that incorporates the provisions outlined in the Uniform Prudent Management of Institutional Funds Act (UPMIFA). The statutory guidelines contained in this legislation relate to the prudent management, investment, and expenditure of donor-restricted endowment funds held by charitable organizations. Additionally, the legislation specifies factors for fiduciaries to consider prior to making a decision to appropriate from or accumulate into an institution's endowment funds.

At June 30, 2020, the university's endowment consists of 3,711 individual donor-restricted endowment funds and Board of Trustees or management-designated endowment funds for a variety of purposes plus split-interest agreements and other net assets where the assets have been designated for endowment. The net assets associated with endowment funds, including funds designated by the Board of Trustees or management to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

The university has interpreted Missouri UPMIFA as requiring the preservation of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, the university classifies as net assets with donor restrictions, (a) the original value of gifts donated to the donor-restricted endowment, (b) the original value of subsequent gifts to the donor-restricted endowment, (c) accumulations to the donor-restricted endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of donor-restricted endowment funds that are not restricted in perpetuity are considered restricted until the donor-imposed stipulations attached to those amounts have been met by actions of the university and/or passage of time and appropriated for expenditure in a manner consistent with the standard of prudence prescribed by UPMIFA.

Endowment net asset composition, which includes the effect of changes in endowment investments as well as other endowment-related assets and liabilities, by type of fund as of June 30, 2020:

	Without Donor Restriction	With Donor Restriction	Total
Donor-restricted endowment funds	\$ -	\$ 5,103,500	\$ 5,103,500
Board-designated endowment funds	<u>3,085,820</u>	<u>299,974</u>	<u>3,385,794</u>
Total endowment funds	<u>\$ 3,085,820</u>	<u>\$ 5,403,474</u>	<u>\$ 8,489,294</u>

Washington University
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

(All amounts in thousands of dollars)

Changes in endowment net assets for the year ended June 30, 2020:

	Without Donor Restriction	With Donor Restriction	Total
Endowment net assets, beginning of year	\$ 2,845,594	\$ 5,163,331	\$ 8,008,925
Investment return			
Net investment income	(24,515)	(33,356)	(57,871)
Net appreciation (realized and unrealized)	446,000	438,638	884,638
Total investment return	421,485	405,282	826,767
Gifts	83	79,937	80,020
Appropriation of endowment assets for expenditure	(150,064)	(211,808)	(361,872)
Net transfers of funds	15,834	(2,815)	13,019
Allocation of endowment return to treasurer's investment pool	(51,171)	(28,772)	(79,943)
Other activity	4,059	(1,681)	2,378
Endowment net assets, end of year	\$ 3,085,820	\$ 5,403,474	\$ 8,489,294

Of the amount classified as endowment net assets with donor restrictions, \$2,434,976 represents the portion of endowment funds subject to time restrictions under Missouri's enacted version of UPMIFA.

Endowment net asset composition by type of fund as of June 30, 2019:

	Without Donor Restriction	With Donor Restriction	Total
Donor-restricted endowment funds	\$ -	\$ 4,891,626	\$ 4,891,626
Board-designated endowment funds	2,845,594	271,705	3,117,299
Total endowment funds	\$ 2,845,594	\$ 5,163,331	\$ 8,008,925

Changes in endowment net assets for the year ended June 30, 2019:

	Without Donor Restriction	With Donor Restriction	Total
Endowment net assets, beginning of year	\$ 2,757,498	\$ 4,882,671	\$ 7,640,169
Investment return			
Net investment income	(15,332)	(18,647)	(33,979)
Net appreciation (realized and unrealized)	282,227	366,179	648,406
Total investment return	266,895	347,532	614,427
Gifts	140	120,479	120,619
Appropriation of endowment assets for expenditure	(147,447)	(193,865)	(341,312)
Net transfers of funds	9,576	30,582	40,158
Allocation of endowment return to treasurer's investment pool	(44,780)	(23,962)	(68,742)
Other activity	3,712	(106)	3,606
Endowment net assets, end of year	\$ 2,845,594	\$ 5,163,331	\$ 8,008,925

Washington University
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

(All amounts in thousands of dollars)

Of the amount classified as endowment net assets with donor restrictions, \$2,686,050 represents the portion of endowment funds subject to time restrictions under Missouri's enacted version of UPMIFA.

Endowment by Purpose

The purpose of endowment funds as of June 30, 2020

	Without Donor Restriction	With Donor Restriction	Total
Restricted for general activities	\$ 2,321,054	\$ 3,621,441	\$ 5,942,495
Restricted for student assistance	407,464	1,013,383	1,420,847
Restricted for buildings and renovations	357,278	743,597	1,100,875
Life income	<u>24</u>	<u>25,053</u>	<u>25,077</u>
Total endowment net assets	<u>\$ 3,085,820</u>	<u>\$ 5,403,474</u>	<u>\$ 8,489,294</u>

The purpose of endowment funds as of June 30, 2019:

	Without Donor Restriction	With Donor Restriction	Total
Restricted for general activities	\$ 2,378,476	\$ 3,473,772	\$ 5,852,248
Restricted for student assistance	315,546	1,015,986	1,331,532
Restricted for buildings and renovations	151,549	634,711	786,260
Life income	<u>23</u>	<u>38,862</u>	<u>38,885</u>
Total endowment net assets	<u>\$ 2,845,594</u>	<u>\$ 5,163,331</u>	<u>\$ 8,008,925</u>

Endowment Funds With Deficits

As determined under UPMIFA, the fair value of assets associated with individual donor-restricted endowment funds may fall below the value of the initial and subsequent donor gift amounts (i.e., deficit). When donor endowment deficits exist, they remain classified as net assets with donor restrictions. Deficits of this nature were immaterial as of June 30, 2020 and 2019, respectively. The deficits resulted largely from unfavorable market fluctuations.

Return Objectives and Risk Parameters

The university has adopted endowment investment and spending policies that attempt to provide a predictable stream of funding to programs supported by its endowment while seeking to maintain the purchasing power of endowment assets. Under this policy, the return objective for the endowment assets, measured over a full market cycle, shall be to meet or exceed the return of its policy benchmark, based on the endowment's target allocation applied to the appropriate individual benchmarks. The university expects its endowment funds, over time, to provide an average rate of return that will exceed the sum of inflation and the spending rate. Actual returns in any given year may vary from this amount.

Strategies Employed for Achieving Investment Objectives

To achieve its long-term rate of return objectives, the university relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized gains) and current yield (interest and dividends). The university targets a diversified global asset allocation that places greater emphasis on equity-based and alternative investments to achieve its long-term objectives within prudent risk constraints.

Washington University
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

(All amounts in thousands of dollars)

Endowment Spending Allocation and Relationship of Spending Policy to Investment Objectives

The university has an endowment spending distribution policy designed to stabilize annual spending levels and preserve the real value of the endowment over time. Under this policy, earnings of the pooled endowment are distributed at a rate set annually to the schools and other units of the university. Consideration is given to the provisions of UPMIFA in determining the amount to appropriate. This spending rate must fall within the range of 3.0% to 5.5% of the five-year average market value of a unit of the pooled endowment. For 2020, the spending rate from the pooled endowment was 4.6% of the beginning market value of the pooled endowment. The spending rate is funded from current earnings and, in years when current earnings are insufficient, from previously accumulated earnings of the endowment.

The university's endowment assets at June 30 are as follows:

	<u>2020</u>	<u>2019</u>
Pooled endowment and other funds	\$ 9,547,820	\$ 9,001,587
Life income trusts and pools	76,091	79,529
Externally administered trusts	30,804	31,533
Separately invested endowment	<u>8,577</u>	<u>9,140</u>
Total	9,663,292	9,121,789
Less: Operating funds invested in pool	<u>(1,148,092)</u>	<u>(991,306)</u>
Net endowment assets	<u>\$ 8,515,200</u>	<u>\$ 8,130,483</u>

The amounts above include term endowments of \$102,870 and \$98,858 as of June 30, 2020 and 2019, respectively.

5. Liquidity and Availability of Resources

At June 30, 2020 and 2019, the university's financial assets available for general expenditures within one year of the balance sheet date are as follows:

	<u>2020</u>	<u>2019</u>
Total assets at year end	\$ 15,103,569	\$ 14,144,232
Less:		
Accounts and notes receivable due in more than one year	(104,244)	(107,520)
Pledges receivable unavailable for general expenditure	(332,861)	(301,655)
Donor-restricted endowment funds	(5,135,123)	(4,981,501)
Board-designated endowment funds	(3,380,076)	(3,148,982)
Other long-term investments	(1,590,748)	(1,173,200)
Other assets	(273,472)	(272,499)
Fixed assets	<u>(2,902,823)</u>	<u>(2,736,428)</u>
Total financial assets available within one year	<u>\$ 1,384,222</u>	<u>\$ 1,422,447</u>

Washington University
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

(All amounts in thousands of dollars)

The university's endowment funds consist of donor-restricted and board-designated endowment funds. As described in Note 4, the university has an endowment spending distribution policy with a spending rate range of 3.0% to 5.5% of the five-year average market value. For fiscal year 2021, the Board of Trustees approved a spending rate which approximates 4.4% of the beginning market value of the pooled endowment. An endowment payout of \$415,230, which includes an allocation to the treasurer's investment pool, will be available for operations during fiscal year 2021.

In addition to these available financial assets, the university's annual expenditures will be primarily funded by current year operating revenues including tuition, patient services income, and sponsored research income. As part of the university's liquidity management, a policy is in place to structure its financial assets to be available as general expenditures, liabilities, and other obligations come due. The university also invests cash in excess of daily requirements in short-term investments. Furthermore, although the university does not intend to spend from its board-designated endowment funds other than amounts appropriated for general expenditure as part of its annual budget approval and appropriation process, amounts from its board-designated endowment that are free from investment restrictions could be made available if necessary. Other long-term investments are primarily composed of amounts designated by the university as reserves. Such investments are without donor restriction and could be drawn upon in the event of extreme stress. In the event of an unanticipated liquidity need, the university could also draw upon available lines of credit which were approximately \$200,000 at June 30, 2020.

6. Accounts and Notes Receivable

Accounts and notes receivable at June 30 were as follows:

	2020	2019
Patient services	\$ 418,149	\$ 472,166
Student and parent loans		
Parent loan fund	44,928	45,076
Government student loans	20,042	26,222
Institutional student loans	21,987	22,333
Due from affiliates	157,276	166,162
Sponsored project receivables	71,590	89,050
Other	98,673	109,352
	<u>832,645</u>	<u>930,361</u>
Less: Allowance for contractual adjustments and doubtful accounts	<u>(280,053)</u>	<u>(309,036)</u>
Total	<u>\$ 552,592</u>	<u>\$ 621,325</u>

Washington University

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(All amounts in thousands of dollars)

7. Notes and Bonds Payable

Outstanding principal on bonds and notes payable at June 30, 2020 and 2019 consists of the following:

	Rates at June 30, 2020	Maturity	2020	2019
Missouri Health and Educational Facilities Authority				
\$142,400 of 1996A, B, C and D Series Variable Rate Bonds, due in full	0.11% - 0.13%	September 1, 2030	\$ 132,400	\$ 142,400
\$88,000 of 2000B and C Series Variable Rate Bonds, due in full	0.11% - 0.12%	March 1, 2040	88,000	88,000
\$25,135 of 2003B Series Variable Rate Bonds, due in full	0.04% - 0.12%	February 15, 2033	25,135	25,135
\$22,985 of 2011A Series Revenue Bonds due in full	5.00%	November 15, 2041	-	22,985
\$96,350 of 2011B Series Revenue Bonds due in full November 15, 2030 (\$39,050) and November 15, 2037 (\$57,300)	5.00%	November 15, 2030 and 2037	-	96,350
\$77,495 of 2011C Series Revenue Bonds due serially from November 15, 2012 to November 15, 2037	.75% - 5.06%	November 15, 2037	51,890	54,360
\$200,785 of 2012A Series Revenue Bonds due serially from February 15, 2023 to February 15, 2047	2.39% - 3.69%	February 15, 2047	200,785	200,785
\$150,000 of 2014A Series Revenue Bonds due in full	4.07%	October 15, 2044	150,000	150,000
\$402,920 of 2016A Series Revenue Bonds due in full January 15, 2036 (\$109,300) and January 15, 2046 (\$293,620)	3.47% - 3.65%	January 15, 2036 and 2046	402,920	402,920
\$272,750 of 2016 B Series Revenue Bonds due in full	3.09%	September 15, 2051	272,750	272,750
\$375,000 of 2017 A Series Revenue Bonds, due in full	3.65%	August 15, 2057	375,000	375,000
\$450,000 of 2020 A Series Revenue Bonds, due in full	3.23%	May 15, 2050	450,000	-
Other Bonds:				
\$131,435 of 2015A Series Taxable Bonds due in full	3.79%	October 15, 2055	131,435	131,435
Other notes payable			145,783	105,377
Total outstanding notes and bonds payable			2,426,098	2,067,497
Unamortized original issue premiums/discounts and cost of issuance, net			(10,756)	(3,410)
Total			\$ 2,415,342	\$ 2,064,087

Bonds payable are redeemable at the option of the university at various times from 2020 through 2057. The university is required to maintain certain ratios and comply with other restrictive covenants principally that the university maintain a ratio of expendable financial resources to debt of at least 1.25 times. The university is in compliance with this covenant. During 2020 and 2019, interest, accretion of debt discount and related fees incurred on notes and bonds payable totaled \$72,003 and \$71,054, respectively.

Maturities on notes and bonds payable for the next five fiscal years are as follows:

2021	\$ 82,612
2022	65,223
2023	22,477
2024	2,577
2025	2,627
Thereafter	2,250,582

Washington University

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(All amounts in thousands of dollars)

During fiscal 2020, the university issued \$450,000 of Series 2020A Missouri Health and Educational Facilities Authority (MOHEFA) bonds. The bonds bear a fixed rate of 3.23% and will mature on May 15, 2050. The proceeds of these bonds will be used to finance various construction projects.

The university has other lines of credit, which generally expire annually, aggregating \$381,220, of which \$235,427 is available at June 30, 2020. The university expects that these lines of credit will be renewed but can make no assurances.

8. Derivative and Other Financial Instruments

The university utilizes derivative instruments including futures, swaps, and options, to manage market risk, to provide temporary investment exposure in stocks and bonds, and to manage currency and interest rate exposures. When directly implementing a derivative strategy, the university uses a third party manager to execute, settle and manage the positions on a non-discretionary basis. These contracts are valued at periodic intervals such as daily, monthly, and quarterly as well as at June 30, with the resulting changes in the values of the contracts either added to or deducted from the university's custodial account. Gains or losses from these derivative instruments are reported as realized and unrealized gains or losses in the Consolidated Statements of Activities. Indirect strategies in derivatives held by limited partnerships and commingled investment trusts in which the university invests pose no off-balance sheet risk to the university due to the limited liability structure of the investments. Derivatives are also used to manage operating expenses but are not material to the consolidated financial statements. No derivative contracts are designated as hedges for accounting purposes.

9. Functional Expenses

Operating expenses are reported on the Consolidated Statements of Activities in natural categories. Expenses reported by functional categories include allocations of costs for operation and maintenance of plant, interest on indebtedness and depreciation expense. Operation and maintenance of plant and depreciation are allocated to functional categories largely based on square footage. Interest expense is allocated based on specific identification of the uses of debt proceeds. Instruction expenses include instruction, departmental research and patient care costs.

Operating expenses by functional and natural classification for the year ended June 30, 2020 are as follows:

	Compensation and benefits	Supplies, services and other	Depreciation	Interest	Total
Instruction	\$ 1,437,775	\$ 772,494	\$ 71,378	\$ 18,769	\$ 2,300,416
Research	349,358	158,325	48,975	13,817	570,475
Academic Support	183,997		32,524	10,652	227,173
Student Services	45,838	45,295	6,125	2,710	99,968
Institutional Support	124,582	58,171	5,362	1,037	189,152
Auxiliary Enterprises	19,624	54,167	35,372	23,058	132,221
Other	22,770	15,459	2,237	157	40,623
Total	<u>\$ 2,183,944</u>	<u>\$ 1,103,911</u>	<u>\$ 201,973</u>	<u>\$ 70,200</u>	<u>\$ 3,560,028</u>

Washington University
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

(All amounts in thousands of dollars)

Operating expenses by functional and natural classification for the year ended June 30, 2019 are as follows:

	Compensation and benefits	Supplies, services and other	Depreciation	Interest	Total
Instruction	\$ 1,345,432	\$ 738,779	\$ 67,951	\$ 18,369	\$ 2,170,532
Research	332,661	155,509	41,961	10,976	541,107
Academic Support	166,972		33,684	11,605	212,260
Student Services	44,379	49,338	6,018	2,793	102,527
Institutional Support	109,307	48,275	5,764	1,151	164,497
Auxiliary Enterprises	18,946	54,136	32,451	20,597	126,130
Other	23,472	14,042	1,029	138	38,681
Total	<u>\$ 2,041,168</u>	<u>\$ 1,060,079</u>	<u>\$ 188,858</u>	<u>\$ 65,629</u>	<u>\$ 3,355,734</u>

10. Commitments and Contingencies

At June 30, 2020, the university had outstanding commitments under certain construction contracts in the amount of \$109,955.

The university maintains a self-insurance program for professional liability at the Medical School and a separate program for Washington University Physicians in Illinois. This program is supplemented with commercial excess insurance above the university's self-insurance retention. Funding for the program reserves is based on claims made. The assets supporting the funded reserve are reported as investments in the Consolidated Statements of Financial Position. The university also accrues for an estimate of claims incurred but not reported. Reserves, funded and unfunded, are based upon actuarial studies and represent undiscounted estimated claims and related costs. The total self-insurance reserves at June 30, 2020 and 2019, respectively, were \$91,493 and \$84,236. Self-insurance reserves are necessarily estimates based on historical loss experience and other factors, and while management believes that the reserves are adequate, the ultimate liabilities may be in excess of or less than the amounts provided.

The university is a party, along with other universities, to an agreement with a reciprocal risk retention group for purposes of obtaining general liability and auto liability insurance coverage in excess of a pre-determined retention level. Under the terms of these agreements, the university can be called upon to make additional capital contributions. In management's view, any such capital calls would not be material.

The university is involved in various legal proceedings arising in the normal course of operations. Although the outcome of any legal proceeding cannot be predicted with certainty, it is the opinion of the university's management that the outcome of these proceedings individually or in the aggregate, will not have a material adverse effect on the business, Consolidated Statements of Activities, financial position or liquidity of the university.

Washington University

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(All amounts in thousands of dollars)

11. Retirement Plan

The university provides its faculty and staff with a defined contribution (403(b)) retirement savings plan in which employee contributions, university contributions and investment earnings accumulate to assist employees at retirement. Participating employees own individual retirement accounts through the Teachers Insurance and Annuity Association (TIAA) and College Retirement Equity Fund (CREF). Under this arrangement, the university and plan participants make monthly contributions to TIAA-CREF. The amount of contribution made by the university is based on employee's hire date, age and/or base salary. Vesting provisions are full and immediate. The university's share of the cost of these benefits in 2020 and 2019 was \$95,214 and \$88,923, respectively. Effective July 1, 2020, employer contributions to the plan have been temporarily suspended through June 30, 2021 in response to the COVID-19 pandemic. The end date for the suspension is subject to change. The university provides dependent tuition benefits to qualified retirees. The liability under this plan was \$22,027 and \$25,136 as of June 30, 2020 and 2019, respectively.

12. Agreements with Affiliated Hospitals

The university has affiliation agreements with Barnes Jewish Hospital (BJH), St. Louis Children's Hospital (SLCH), and Barnes Jewish West County Hospital (BJWCH), collectively the Hospitals, which expire December 31, 2027, but may be canceled upon a one-year written notice by either party. These agreements relate to various operating activities of the Hospitals including Orthopedic Center (OC) in Chesterfield, the Siteman Cancer Center – South County, Center for Advanced Medicine (CAM) in South County, BJH Psychiatric Support Center (PSC), and the Children's Specialty Care Center in Town and Country.

Under the terms of the affiliation agreement, the university trains and supervises medical residents and interns and manages certain clinical and research activities of the Hospitals. BJH, SLCH, and BJWCH are responsible for the hospitals and health care delivery facilities and compensate the university for services provided by the university through a fixed annual base payment (adjusted annually for inflation) plus an additional variable payment based on the combined Hospitals' net operating income. In addition, the university derives revenue from patient services provided at Barnes-Jewish at St. Peters Hospital under an agreement with that hospital and BJH. Payments to the university under affiliation agreements are reported as affiliated hospital revenue on the Consolidated Statements of Activities (see footnote 1). During 2013, BJH agreed to fund on a cost-reimbursement basis over a period of years, certain expenditures by the university. Payments of \$21,507 and \$36,652 were received or accrued as gifts on the Consolidated Statements of Activities under the agreement during 2020 and 2019, respectively.

13. Subsequent Events

The university has performed an evaluation of subsequent events through October 2, 2020, which is the date the consolidated financial statements were issued.

Supplementary Information

Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2020

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Research and Development Cluster					
DEPARTMENT OF DEFENSE					
Advanced Research Projects Agency					
Research and Technology Development	12.910			\$ (326)	\$ -
Research and Technology Development	12.910	Vanderbilt University Medical Center	HR00111820001	397,278	-
COVID19-Research and Technology Development	12.910	Vanderbilt University Medical Center	HR00111820001	250,720	-
Research and Technology Development	12.910	Wesleyan University	HR00111820042	15,647	-
Defense Advanced Research Projects Agency					
Defense Advanced Research Projects Agency	12.RD	Leaflab, LLC	HR00111990036	24,253	-
Defense Advanced Research Projects Agency	12.RD	Raytheon BBN Technologies Corporation	HR001117C0049	129,360	-
Defense Advanced Research Projects Agency	12.RD	Two Six Labs	HR00117C0111	639,929	-
Defense Threat Reduction Agency					
Basic Scientific Research - Combating Weapons of Mass Destruction	12.351			893,134	520,907
Basic Scientific Research - Combating Weapons of Mass Destruction	12.351	Georgia State University	HDTRA11610033	9,434	-
Department of Defense					
Department of Defense	12.RD	Cepheid Inc.	W15QKN-16-9-1002	82,471	-
Uniformed Services University Medical Research Projects	12.750	Metis Foundation	HU00011920029	78,433	-
Department of Defense	12.RD	North Carolina State University	H9823019D0012	89,790	-
Department of the Air Force, Material Command					
Air Force Defense Research Sciences Program	12.800			364,892	18,908
Air Force Defense Research Sciences Program	12.RD	Massachusetts Institute of Technology	FA870215D0001	(667)	-
Air Force Defense Research Sciences Program	12.RD	Nanosonic	AF10383	7,484	-
Air Force Defense Research Sciences Program	12.RD	Raytheon BBN Technologies Corporation	FA875019C0056	82,895	-
Air Force Defense Research Sciences Program	12.800	UES, INC.	FA8650-14-D-6516	3,153	-
Air Force Defense Research Sciences Program	12.800	Vanderbilt University	FA95501810126	37,731	-
Department of the Navy, Office of the Chief of Naval Research					
Applied Research and Exploratory Development	12.RD			1,136	-
Basic and Applied Scientific Research	12.300			1,056,653	-
Basic and Applied Scientific Research	12.300	University of California, Davis	N000141712961	328,693	-
Basic and Applied Scientific Research	12.300	University of Southern California	N000141812632	119,967	-
U.S. Army Medical Command					
Military Medical Research and Development	12.RD	Arizona State University	W911NF19C0039	316,820	-
Military Medical Research and Development	12.RD	Biofire Defense LLC	W911QY13D0080	(8,384)	-
Military Medical Research and Development	12.RD	CFD Research Corporation	W911QY17C0008	1,679	-
Basic Scientific Research	12.431			276,304	24,515
Basic Scientific Research	12.431	Leonard Wood Institute	W911NF1420034	66,248	-
Basic Scientific Research	12.431	University of Michigan	SUBK00009859	132,568	-
Basic Scientific Research	12.431	University of Minnesota	W911NF1810240	172,731	-
Basic Scientific Research	12.431	Vanderbilt University	W911NF161069	7,310	-
U.S. Army Medical Command					
Military Medical Research and Development	12.RD			989,224	455,559
Military Medical Research and Development	12.RD	Johns Hopkins University	USAMRA (DOD)	484	-
Military Medical Research and Development	12.RD	Johns Hopkins University	W81XWH1810815	3,416	-
Military Medical Research and Development	12.RD	SARC	W81XWH1710695	30,584	-
Military Medical Research and Development	12.RD	University of Maryland, Baltimore	W81XWH1710668	12,499	-
Military Medical Research and Development	12.420			8,499,219	370,181
Military Medical Research and Development	12.420	Boston Children's Hospital	W81XWH1710532	24,660	-
Military Medical Research and Development	12.420	Brigham and Women's Hospital	W81XWH1510269	34,214	-
Military Medical Research and Development	12.420	Idibiologics	W81XWH1910405	34,480	-
Military Medical Research and Development	12.420	Johns Hopkins University	W81XWH-15-2-0067	2,562	-
Military Medical Research and Development	12.420	Northern California Institute for Research and Education	W81XWH1310259	3,890	-
Military Medical Research and Development	12.420	Sarcoma Alliance	W81XWH1310072	374	-
Military Medical Research and Development	12.420	St. Louis College of Pharmacy	W81XWH1610235	8,409	-
Military Medical Research and Development	12.420	St. Louis University	W81XWH1910117	18,742	-
Military Medical Research and Development	12.420	St. Louis University	WX81XWH1810140	3,439	-
Military Medical Research and Development	12.420	University of Alabama, Birmingham	W81XWH1720037	4,080	-
Military Medical Research and Development	12.420	University of California, San Diego	W81XWH1710393	7,631	-
Military Medical Research and Development	12.420	University of Colorado	W81XWH1510504	63,092	-
Military Medical Research and Development	12.420	University of Minnesota	W81XWH1710633	12,025	-
Military Medical Research and Development	12.420	University of Missouri	W81XWH1520037	78,020	-
Military Medical Research and Development	12.420	University of Pittsburgh	W81XWH1720073	1,041	-
Military Medical Research and Development	12.420	Veterans Research and Education Foundation	W81XWH1810548	328,493	-
TOTAL DEPARTMENT OF DEFENSE				15,737,914	1,390,070

The accompanying notes are an integral are of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2020

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
DEPARTMENT OF EDUCATION					
Office of Postsecondary Education					
Graduate Assistance in Areas of National Need	84.200			169,669	-
Office of Special Education and Rehabilitative Services					
Special Education - Personnel Development to Improve Services and Results for Children with Disabilities	84.325			697,520	-
Special Education - Personnel Development to Improve Services and Results for Children with Disabilities	84.325	Salus University	H325H140002	78,250	-
TOTAL DEPARTMENT OF EDUCATION				945,439	-
DEPARTMENT OF ENERGY					
Department of Energy					
Office of Science Financial Assistance Program	81.049			3,910,058	942,049
Office of Science Financial Assistance Program	81.049	Aerosol Dynamics	DESC0013103	153,359	-
Office of Science Financial Assistance Program	81.049	Aerosol Dynamics	DESC0020495	11,377	-
Office of Science Financial Assistance Program	81.049	Georgia Tech	DESC0012577	37,550	-
Office of Science Financial Assistance Program	81.049	Michigan State University	DESC0013617	120,495	-
Office of Science Financial Assistance Program	81.049	TDA Research, Inc	DE-SC0018502	31,688	-
Renewable Energy Research and Development	81.087			298,573	124,643
Renewable Energy Research and Development	81.087	West Virginia Research Corporation	DEP10000017	375,359	-
Fossil Energy Research and Development	81.089	Linde LLC	DEFEO031592	336,351	-
Fossil Energy Research and Development	81.089	University of Illinois, Urbana-Champaign	DEFEO029161	129,632	-
Stewardship Science Grant Program	81.112			138,158	-
Stewardship Science Grant Program	81.112	Texas A&M University	DENA0003841	112,372	-
Advanced Research Projects Agency - Energy	81.135			428,756	82,673
Advanced Research Projects Agency - Energy	81.135	Danforth Plant Science Center	DEAR0000594	23,271	-
Department of Energy	81.RD			101,563	-
Department of Energy	81.RD			78,789	-
Department of Energy	81.RD	Battelle Memorial Institute	394636	47,952	-
Department of Energy	81.RD	Brookhaven National Lab	351623	85,972	-
Department of Energy	81.RD	National Renewable Energy Laboratory	DEAC3609GO28308	21,352	-
Department of Energy	81.RD	University of California, Lawrence Berkeley National Laboratory	DEAC0205CH11231	114,817	-
TOTAL DEPARTMENT OF ENERGY				6,557,444	1,149,365
DEPARTMENT OF HEALTH AND HUMAN SERVICES					
Administration for Children and Families					
Healthy Marriage Promotion and Responsible Fatherhood Grants	93.086	Father's Support Center St. Louis	HHS2015ACFOFAFK0993	167,272	-
Administration for Children and Families	93.RD	Vision for Children	PACTSTL	32,483	-
Administration for Community Living					
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433			435,538	113,880
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Gallaudet University	90RE50200201	17	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Platform STL	90BISA00150100	20,252	-
Alzheimer's Disease Initiative	93.763	Memory Home Care Solutions	90ALGG00210100	26,841	-
ACL Assistive Technology State Grants for Protection and Advocacy	93.843	Tulane University	2R01HL12242606A1	6,685	-
Agency for Healthcare Research and Quality					
Research on Healthcare Costs, Quality and Outcomes	93.226			1,507,105	130,295
Research on Healthcare Costs, Quality and Outcomes	93.226	Indiana University	R01HS02541102	6,819	-
Research on Healthcare Costs, Quality and Outcomes	93.226	University of Iowa	5R01HS02672402	26,143	-
Research on Healthcare Costs, Quality and Outcomes	93.226	University of Maryland, Baltimore	5R01HS02545602	133,235	-
Research on Healthcare Costs, Quality and Outcomes	93.226	University of Maryland, Baltimore	5R01HS02545603	16,252	-
Centers for Disease Control					
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084			1,561,529	192,665
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Duke University	5U54CK00048303	6,256	4,102
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Duke University	U54CK00048304	42,339	1,749
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Rush University	5U54CK00048104	999	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Rush University	6U54CK00048102	124,194	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Rush University	6U54CK00048103	(12)	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	University of Pennsylvania	5U54CK00048502	(1,635)	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	University of Pennsylvania	5U54CK00048504	40,976	-
Research on Research Integrity	93.085			62,427	-
Centers for Research and Demonstration for Health Promotion and Disease Prevention	93.135			445,001	-
Occupational Safety and Health Program	93.262			762,415	307,251
Occupational Safety and Health Program	93.262	Center For Construction Research & Training	5U600H00976209	46,931	-
Occupational Safety and Health Program	93.262	Center For Construction Research & Training	U600H00976211	282,944	-
Occupational Safety and Health Program	93.262	University of California, San Diego	1R01OH11661	129,814	-
Occupational Safety and Health Program	93.262	University of Colorado	5U19OH01122704	3,150	-
Occupational Safety and Health Program	93.262	University of Iowa	5U100H00886814	38,080	-

The accompanying notes are an integral part of this schedule.

Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2020

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Occupational Safety and Health Program	93.262	University of Iowa	5U19OH00886813	33,914	-
Occupational Safety and Health Program	93.262	University of Iowa	5U19OH00886814	112,940	-
Centers for Disease Control and Prevention, Investigations and Technical Assistance	93.283			849,190	410,870
National Public Health Improvement Initiative	93.292	Center For Construction Research & Training	U60OH009762	36,972	-
Early Hearing Detection and Intervention Information System Surveillance Program	93.314	University of Kansas Medical Center	7U13HS338780100	2,561	-
Childhood Obesity Research Demonstration	93.349			702,189	151,775
National Organizations for Chronic Disease Prevention and Health Promotion	93.809	National Association For Chronic Disease Director	1NU58DP00651001	92,943	-
National Organizations for Chronic Disease Prevention and Health Promotion	93.809	National Association For Chronic Disease Director	1NU58DP00651002	102,411	-
Ebola Support: Transmission and Prevention Control, Public Health Preparedness, Vaccine Development	93.823	Emory University	A022895	(638)	-
Capacity Building Assistance for High-Impact HIV Prevention	93.834			90,216	90,183
Preventive Health Services	93.977			256,998	6,158
Sexually Transmitted Diseases (STD) Provider Education Grants	93.978			54,020	-
Centers for Disease Control	93.RD			132,331	-
Centers for Disease Control	93.RD	St. Louis County	DP181817	219,581	14,764
Food and Drug Administration					
Food and Drug Administration_Research	93.103	Columbia University	5R01FD00574502	1,833	-
Food and Drug Administration_Research	93.103	Massachusetts General Hospital	1U01FD00686801	10,631	-
Food and Drug Administration_Research	93.RD	University of Southern California	HHSF223201400115C	5,592	-
Health Resources and Services Administration					
Grants to Increase Organ Donations	93.134	Johns Hopkins University	1R39OT311030100	19,344	-
Grants to Increase Organ Donations	93.134	Johns Hopkins University	5R39OT311030300	48,204	-
Rural Health Research Centers	93.155	University of Iowa	5U1CRH204191100	91,787	-
Rural Health Research Centers	93.155	University of Iowa	6U1CRH204191001	26,894	-
IMMED Office of the Secretary of Health and Human Services					
Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development	93.360	Integrated Biotherapeutics Inc	IDSEP160030-02	8,887	-
National Institutes of Health					
Environmental Health	93.113			3,415,313	420,714
Environmental Health	93.113	Baylor College of Medicine	5U01ES02671905	64,082	-
Environmental Health	93.113	Colorado State University	1R01ES03093701	11,969	-
Environmental Health	93.113	Johns Hopkins University	5R01ES02696102	70,348	-
Oral Diseases and Disorders Research	93.121			1,546,153	169,357
Oral Diseases and Disorders Research	93.121	University of Louisville	1R01DE02829601A1	8,079	-
NIEHS Superfund Hazardous Substances_Basic Research and Education	93.143	University of Louisville	5P42ES02371602	28,246	-
NIEHS Superfund Hazardous Substances_Basic Research and Education	93.143	University of Louisville	P42ES023716	174,517	21,176
Human Genome Research	93.172			22,744,944	1,265,150
Human Genome Research	93.172	California Institute of Technology	2U24HG0022319	(207)	-
Human Genome Research	93.172	California Institute of Technology	U24HG002223	38,041	-
Human Genome Research	93.172	Ecog-Acrin Cancer Research Group	U10CA180820	(3,442)	-
Human Genome Research	93.172	Geisinger Clinic	5R01HG00967102	14,350	-
Human Genome Research	93.172	Harvard University	5U01HG00753006	102,385	-
Human Genome Research	93.172	Nationwide Children's Hospital	3U41HG0076350451	97,646	-
Human Genome Research	93.172	New York Genome Center	5UM1HG00890104	41,773	-
Human Genome Research	93.172	Stanford University	5UM1HG00944203	130,307	-
Human Genome Research	93.172	Stanford University	5UM1HG00944204	43,502	-
Human Genome Research	93.172	The Broad Institute	1U24HG01026202	176,506	-
Human Genome Research	93.172	The Jackson Laboratory	2U24HG00749705	9,016	-
Human Genome Research	93.172	University of California, Santa Cruz	1U01HG01097101	227,638	-
Human Genome Research	93.172	Vanderbilt University	5RM1HG009034	74,243	-
Research Related to Deafness and Communication Disorders	93.173			7,924,635	506,897
Research Related to Deafness and Communication Disorders	93.173	Customized Learning Exercises for Aural Rehabilitation, Inc.	1R43DC01824701	52,143	-
Research Related to Deafness and Communication Disorders	93.173	East Carolina University	1R01DC01770201	20,148	-
Research Related to Deafness and Communication Disorders	93.173	Father Flanagan's Boys Home	5R01DC01538505	130,049	-
Research Related to Deafness and Communication Disorders	93.173	Gateway Biotechnology, Inc.	1R41DC01740601	5,942	-
Research Related to Deafness and Communication Disorders	93.173	Northwestern University	5R01DC01627302	3,130	-
Research Related to Deafness and Communication Disorders	93.173	University of Alabama	5R01DC01598002	108,185	-
Research Related to Deafness and Communication Disorders	93.173	University of Michigan	1R01DC01609902	8,860	-
Research Related to Deafness and Communication Disorders	93.173	University of Nevada, Reno	5P01AG05144302	188,019	31,165
Research Related to Deafness and Communication Disorders	93.173	University of Nevada, Reno	5R01DC01513502	27,145	-
Research Related to Deafness and Communication Disorders	93.173	University of Pittsburgh	2R0DC01304806A1	51,361	-
Research Related to Deafness and Communication Disorders	93.173	University of Southern California	1R01DC01774101A1	17,757	-
Research Related to Deafness and Communication Disorders	93.173	University of Utah	2R01DC01131107	36,649	-
Research Related to Deafness and Communication Disorders	93.173	University of Utah	2R01DC01131108	5,667	-
Research and Training in Complementary and Integrative Health	93.213			1,034,607	-

The accompanying notes are an integral are of this schedule.

Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2020

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Mental Health Research Grants	93.242			29,554,223	6,261,253
Mental Health Research Grants	93.242	Centre for Addiction and Mental Health	1R01MH11831101A1	9,895	-
Mental Health Research Grants	93.242	Chapman University	2P50MH09688906A1	39,358	-
Mental Health Research Grants	93.242	Columbia University	1R01MH12059701	13,181	-
Mental Health Research Grants	93.242	Duke University	5R01MH11048804	1,607	-
Mental Health Research Grants	93.242	Duke University	5R01MH11048805	2,416	-
Mental Health Research Grants	93.242	Emory University	1R01MH11469203	10,455	-
Mental Health Research Grants	93.242	Emory University	5R01MH11469202	(3,342)	-
Mental Health Research Grants	93.242	Emory University	5R01MH11469203	210,089	-
Mental Health Research Grants	93.242	Emory University	5R01MH11828502	15,230	-
Mental Health Research Grants	93.242	Geisinger Clinic	5R01ES02696102	110,629	-
Mental Health Research Grants	93.242	Geisinger Clinic	5U01MH11970502	49,980	-
Mental Health Research Grants	93.242	Indiana University	5R01MH10846704	67,329	-
Mental Health Research Grants	93.242	Johns Hopkins University	5R01ES02696102	36,814	-
Mental Health Research Grants	93.242	Kitware, Inc.	1R41MH11884501	73,302	-
Mental Health Research Grants	93.242	Kitware, Inc.	3R41MH11884502S1	5,567	-
Mental Health Research Grants	93.242	NeuroLux, Inc.	1R41MH11652502	77,268	-
Mental Health Research Grants	93.242	New York University	1P50MH11366201A1	93,097	-
Mental Health Research Grants	93.242	New York University	3P50MH113662-01A1S1	52,359	-
Mental Health Research Grants	93.242	New York University	PS0MH11366201A1	40,922	-
Mental Health Research Grants	93.242	Nous Imaging	1R44MH12206601	126,694	-
Mental Health Research Grants	93.242	Research Foundation Mental Hygiene	5P50MH11584302	24,429	-
Mental Health Research Grants	93.242	Research Foundation Mental Hygiene	5P50MH11584303	24,687	-
Mental Health Research Grants	93.242	Rutgers University	2U24MH06845716	1,458	-
Mental Health Research Grants	93.242	Rutgers University	7U24MH06845717	83,842	-
Mental Health Research Grants	93.242	Rutgers University	U24MH068457	4,668	-
Mental Health Research Grants	93.242	St. Louis College of Pharmacy	5R01MH09276911	92,284	-
Mental Health Research Grants	93.242	St. Louis College of Pharmacy	R01MH09276911	35,148	-
Mental Health Research Grants	93.242	State University of New York	5U01HL13155203	(14,537)	-
Mental Health Research Grants	93.242	State University of New York	5U01HL13155204	587,433	-
Mental Health Research Grants	93.242	The Miriam Hospital	1R01MH11465703	129,506	-
Mental Health Research Grants	93.242	Universidad De O'Higgins	1U01MH11550201	42,625	-
Mental Health Research Grants	93.242	University of Alabama, Birmingham	1R34MH12110301	25,047	-
Mental Health Research Grants	93.242	University of Alabama, Birmingham	5R01MH11678902	10,294	-
Mental Health Research Grants	93.242	University of California, Los Angeles	1R01MH12146201	35,980	-
Mental Health Research Grants	93.242	University of California, Los Angeles	5R01MH10002713	351,606	-
Mental Health Research Grants	93.242	University of California, San Diego	5R01MH10734504	95,730	-
Mental Health Research Grants	93.242	University of Minnesota	1R01MH11696102	23,793	-
Mental Health Research Grants	93.242	University of Missouri, St. Louis	R01MH108559	148,459	-
Mental Health Research Grants	93.242	University of North Carolina at Chapel Hill	3U01MH11092503S1	1,133	-
Mental Health Research Grants	93.242	University of North Carolina at Chapel Hill	5U01MH11092504	348,399	-
Mental Health Research Grants	93.242	University of South Carolina	7R01MH10638802	31,471	-
Mental Health Research Grants	93.242	University of Washington	5R01MH10854804	8,314	-
Mental Health Research Grants	93.242	University of Washington	5R01MH11152004	70,301	-
Mental Health Research Grants	93.242	Yale University	5R01MH10859003	12,987	-
Mental Health Research Grants	93.242	Yale University	5R01MH11274603	29,368	-
Alcohol Research Programs	93.273			2,681,613	217,478
Alcohol Research Programs	93.273	Johns Hopkins University	5R01AA023483	12,126	-
Alcohol Research Programs	93.273	Research Foundation For The State University of New York	5U10AA00840128	(38)	-
Alcohol Research Programs	93.273	Research Foundation For The State University of New York	5U10AA00840130	335,402	-
Alcohol Research Programs	93.273	Research Foundation For The State University of New York	5U10AA00840131	753,035	-
Alcohol Research Programs	93.273	RTI International	1R01AA02704901A1	14,183	-
Alcohol Research Programs	93.273	University of California, San Francisco	R34AA027983	9,440	-
Alcohol Research Programs	93.273	University of Illinois, Urbana-Champaign	7R01AA02410303	18,146	-
Alcohol Research Programs	93.273	Yale University	5R01AA02354904	10,414	-
Drug Abuse and Addiction Research Programs	93.279			9,134,067	529,007
COVID19-Drug Abuse and Addiction Research Programs	93.279			7,318	-
Drug Abuse and Addiction Research Programs	93.279	Benton Technologies	1R43DA04697401	18,508	-
Drug Abuse and Addiction Research Programs	93.279	Duke University	7R01DA04298502	6,194	-
Drug Abuse and Addiction Research Programs	93.279	Eastern Virginia Medical School	1R01DA04675701	9,015	-
Drug Abuse and Addiction Research Programs	93.279	Johns Hopkins University	1R21DA04779501	3,432	-
Drug Abuse and Addiction Research Programs	93.279	Johns Hopkins University	5R01DA04209404	2,888	-

The accompanying notes are an integral part of this schedule.

Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2020

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Drug Abuse and Addiction Research Programs	93.279	McClean Hospital	3UG2DA0158311859	6,177	-
Drug Abuse and Addiction Research Programs	93.279	Neurowave Systems, Inc.	1R43DA04962001	70,038	-
Drug Abuse and Addiction Research Programs	93.279	Rissana LLC	1R24DA05023201	75,125	-
Drug Abuse and Addiction Research Programs	93.279	RTI International	1R01DA04209001	75,049	-
Drug Abuse and Addiction Research Programs	93.279	RTI International	1R01DA04401401	34,138	-
Drug Abuse and Addiction Research Programs	93.279	RTI International	5R01DA03863204	117,124	-
Drug Abuse and Addiction Research Programs	93.279	St. Louis College of Pharmacy	5R21DA04865002	21,502	-
Drug Abuse and Addiction Research Programs	93.279	St. Louis University	1R01DA04381101A1	29,774	-
Drug Abuse and Addiction Research Programs	93.279	University of California, San Diego	3U24DA0411470452	(3,360)	-
Drug Abuse and Addiction Research Programs	93.279	University of California, San Diego	5U24DA04114705	42,732	-
Drug Abuse and Addiction Research Programs	93.279	University of Minnesota	5U01DA04112004	(13,615)	-
Drug Abuse and Addiction Research Programs	93.279	University of Minnesota	5U01DA04112005	1,363,616	-
Drug Abuse and Addiction Research Programs	93.279	University of North Carolina, Chapel Hill	5R01DA04787602	11,519	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286			5,294,346	122,386
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Cornell University	5R21EB02436602	35,187	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Florida International University	5R01EB02758402	6,055	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Kitware, Inc.	5R01EB02139602	20,343	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Tetraimaging, Llc	1R41EB02640101A1	52,497	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University Of Connecticut	1U01EB02889801	86,688	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University Of Delaware	R01EB027577A	133,197	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Illinois, Urbana-Champaign	1R01EB02865201	55,354	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Illinois, Urbana-Champaign	7R01EB02060404	67,808	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Illinois, Urbana-Champaign	7R01EB02304504	145,921	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University Of Massachusetts	5U01EB02195603	9	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University Of Massachusetts	5U01EB02195604	195,919	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University Of Pittsburgh	5R01EB01913504	33,589	-
Minority Health and Health Disparities Research	93.307			582,141	124,910
Minority Health and Health Disparities Research	93.307	Pulse Therapeutics	1R43MD01241801A1	8,501	-
Minority Health and Health Disparities Research	93.307	University of Pittsburgh	5R01MD000911805	17,555	-
Minority Health and Health Disparities Research	93.307	University Of Texas Health Science Center At Houston	5U24MD00694105	25	-
Trans-NIH Research Support	93.310			1,859,087	1,077
Trans-NIH Research Support	93.310	Brigham and Women's Hospital	4UG3OD02326803	63,808	-
Trans-NIH Research Support	93.310	Brigham and Women's Hospital	5UH3OD02326804	315,599	-
Trans-NIH Research Support	93.310	Drexel University	5UG3OD02334202	19,627	-
Trans-NIH Research Support	93.310	Duke University	3UCOD02337504S1	3,343	-
Trans-NIH Research Support	93.310	Duke University	5U2COD02337502	4,229	-
Trans-NIH Research Support	93.310	Duke University	5U2COD02337503	3,389	-
Trans-NIH Research Support	93.310	Duke University	5U2COD02337504	8,249	-
Trans-NIH Research Support	93.310	Stanford University	1U54HG01042602	68,207	-
Trans-NIH Research Support	93.310	University of California, San Diego	1U54HL14560801	183	-
Trans-NIH Research Support	93.310	University of California, San Diego	5U54HL14560802	199,595	-
Trans-NIH Research Support	93.310	University of North Carolina at Chapel Hill	5U24DK1162040102	43,494	-
Trans-NIH Research Support	93.310	University of North Carolina at Chapel Hill	5U24DK1162040403	227,878	-
Trans-NIH Research Support	93.310	University of North Carolina at Chapel Hill	5U24DK11620403	199,442	-
Trans-NIH Research Support	93.310	University of Wisconsin, Madison	4UG3OD02328203	45,422	-
Trans-NIH Research Support	93.310	University of Wisconsin, Madison	5UH3OD02328204	291,702	-
National Center for Advancing Translational Sciences	93.350			11,717,439	348,716
National Center for Advancing Translational Sciences	93.350	Boston Children's Hospital	1U01TR00262301A1	34,903	-
National Center for Advancing Translational Sciences	93.350	Duke University	5U01TR00180303	500	-
National Center for Advancing Translational Sciences	93.350	Dystonia Medical Research Foundation	U54TR001456	12,983	-
National Center for Advancing Translational Sciences	93.350	Oregon Health And Science University	5U24TR00230602	7,887	7,887
National Center for Advancing Translational Sciences	93.350	Oregon Health And Science University	5U24TR00230602	(8,742)	-
National Center for Advancing Translational Sciences	93.350	Oregon Health And Science University	5U24TR00230603	195,115	-
National Center for Advancing Translational Sciences	93.350	Precision Virologics	7R41TR00186902	25,432	-
National Center for Advancing Translational Sciences	93.350	University of Pittsburgh	5U11TR00185702	38,846	-
National Center for Advancing Translational Sciences	93.350	Vanderbilt University Medical Center	5U01TR00239802	80,078	-
National Center for Advancing Translational Sciences	93.350	Vanderbilt University Medical Center	U01TR002398	13,155	-
National Center for Advancing Translational Sciences	93.350	Yale University	ULTR0018630252	(99,371)	-
Research Infrastructure Programs	93.351			5,804,989	638,081
Research Infrastructure Programs	93.351	Columbia University	1R21TR00202901A1	6,603	-
Research Infrastructure Programs	93.351	Cornell University	2P40OD096415	14,543	-
Research Infrastructure Programs	93.351	Texas State University	5R24OD01112010	(6)	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353			5,092,285	209,001

The accompanying notes are an integral part of this schedule.

Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2020

Cluster Title/Federal Grantor/Program Title	CFDA		Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
	Number	Pass Through Entity			
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Duke University	1U2CA23325401	59,806	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Fred Hutchinson Cancer Research	2UM1CA15496707	45,500	-
Nursing Research	93.361			1,777,670	328,167
Nursing Research	93.361	Barnes Jewish Hospital	1R15NR01682801A1	(516)	-
Nursing Research	93.361	Brightoutcome Inc.	5R44NR01618303	11,715	11,715
Nursing Research	93.361	Brightoutcome Inc.	5R44NR01618303	(1,220)	-
Nursing Research	93.361	University of California, Irvine	R01NR105591	(19,137)	-
Nursing Research	93.361	University of California, San Francisco	5R01NR01522305	2,877	-
Cancer Cause and Prevention Research	93.393			8,096,616	773,443
Cancer Cause and Prevention Research	93.393	Baylor University	1U19CA20365402	9,228	-
Cancer Cause and Prevention Research	93.393	Baylor University	5U19CA20365403	31,605	-
Cancer Cause and Prevention Research	93.393	Mayo Clinic	5U01CA19556804	(76)	-
Cancer Cause and Prevention Research	93.393	Mayo Clinic	5U01CA19556805	85,893	-
Cancer Cause and Prevention Research	93.393	Memorial Sloan Kettering Cancer Center	5R01CA22323102	81,155	-
Cancer Cause and Prevention Research	93.393	Northwestern University	1R01CA21843601	9,790	-
Cancer Cause and Prevention Research	93.393	Northwestern University	5R01CA21843603	23,200	-
Cancer Cause and Prevention Research	93.393	Northwestern University	R01CA218436	10,711	-
Cancer Cause and Prevention Research	93.393	Ohio State University	5P01CA10073013	66,830	-
Cancer Cause and Prevention Research	93.393	Ohio State University	5P01CA10073015	86,670	-
Cancer Cause and Prevention Research	93.393	Opencell Technologies	1R43CA23315301	21,669	-
Cancer Cause and Prevention Research	93.393	Quantitative Radiology Solutions	2R42CA19973502	42,628	-
Cancer Cause and Prevention Research	93.393	Research Foundation For The State University of New York	5R01CA19735104	8,978	-
Cancer Cause and Prevention Research	93.393	Stanford University	5R01CA19369404	48,614	-
Cancer Cause and Prevention Research	93.393	Stanford University	5R01CA19369405	14,649	-
Cancer Cause and Prevention Research	93.393	University of California, Berkeley	3P01CA09258419S1	48,926	-
Cancer Cause and Prevention Research	93.393	University of California, San Francisco	5R01CA185687	17,055	-
Cancer Cause and Prevention Research	93.393	University Of Connecticut	5R01CA22025402	20,938	-
Cancer Cause and Prevention Research	93.393	University of Iowa	5R01CA19324905	116,200	-
Cancer Cause and Prevention Research	93.393	University of Massachusetts, Worcester	5R01CA22501802	29,702	-
Cancer Cause and Prevention Research	93.393	University of Missouri	5R01CA20399904	14,415	-
Cancer Cause and Prevention Research	93.393	University of North Carolina at Chapel Hill	5R01CA21605102	84,136	-
Cancer Cause and Prevention Research	93.393	University of North Carolina at Chapel Hill	5P01CA22559702	644,075	-
Cancer Cause and Prevention Research	93.393	University of Texas M.D. Anderson	5R01CA20721604	62,972	-
Cancer Cause and Prevention Research	93.393	University of Utah	5U01CA20611003	52,470	-
Cancer Cause and Prevention Research	93.393	University of Utah	5U01CA20611004	281,899	-
Cancer Cause and Prevention Research	93.393	Vanderbilt University	5R01CA220050502	24,954	-
Cancer Cause and Prevention Research	93.393	Wake Forest University	1R01CA2266078	212,663	-
Cancer Detection and Diagnosis Research	93.394			8,513,680	1,920,455
Cancer Detection and Diagnosis Research	93.394	Boston University	5R01CA20859903	1,598	-
Cancer Detection and Diagnosis Research	93.394	Lasmed LLC	1R43CA20679601A1	26,989	-
Cancer Detection and Diagnosis Research	93.394	New York University School of Medicine	5U24CA1097204	184,225	-
Cancer Detection and Diagnosis Research	93.394	New York University School of Medicine	5U24CA21097203	45,088	-
Cancer Detection and Diagnosis Research	93.394	Princeton University	5U24CA21100002	(838)	-
Cancer Detection and Diagnosis Research	93.394	Princeton University	5U24CA21100003	7,596	-
Cancer Detection and Diagnosis Research	93.394	Princeton University	5U24CA21100004	10,519	-
Cancer Detection and Diagnosis Research	93.394	University of Arkansas	U24CA215109	14,464	-
Cancer Detection and Diagnosis Research	93.394	University of Arkansas Health Sciences	5U01CA18701305	5,743	-
Cancer Detection and Diagnosis Research	93.394	University of California, San Francisco	5R01CA21214803	225,501	-
Cancer Detection and Diagnosis Research	93.394	University of Illinois	4R01CA02583636	7,535	-
Cancer Detection and Diagnosis Research	93.394	University of Illinois, Urbana-Champaign	1R01CA23387301A1	26,697	-
Cancer Detection and Diagnosis Research	93.394	University of Miami	1U01CA23336301	35,488	-
Cancer Detection and Diagnosis Research	93.394	University of Miami	5U01CA23336302	207,804	-
Cancer Detection and Diagnosis Research	93.394	University of Pennsylvania	5R01CA20426104	21,516	-
Cancer Detection and Diagnosis Research	93.394	University of Pittsburgh Medical Center	5U01CA20046603	935	-
Cancer Detection and Diagnosis Research	93.394	Vanderbilt University Medical Center	5U01CA15266209	550	-
Cancer Treatment Research	93.395			12,481,707	1,175,900

The accompanying notes are an integral are of this schedule.

Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2020

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Cancer Treatment Research	93.395	Accuronix Therapeutics	1R41CA23985301A1	37,664	-
Cancer Treatment Research	93.395	American College Of Radiology	1U24CA18080307IROC	2,694	-
Cancer Treatment Research	93.395	American College Of Radiology	2U24CA18080306	(24,876)	-
Cancer Treatment Research	93.395	Brigham & Women's Hospital	3U10CA1808210551	15,238	-
Cancer Treatment Research	93.395	Brigham & Women's Hospital	U10CA180821	-	-
Cancer Treatment Research	93.395	Children's Hospital Of Philadelphia	1U10CA18088601	(3,504)	-
Cancer Treatment Research	93.395	Children's Hospital Of Philadelphia	1UG1CA18995501	1,997	-
Cancer Treatment Research	93.395	Children's Hospital Of Philadelphia	1UM1CA22882301	42,868	-
Cancer Treatment Research	93.395	Children's Hospital Of Philadelphia	2U10CA180886	48,141	-
Cancer Treatment Research	93.395	Children's Hospital Of Philadelphia	2U10CA18088606	38,863	-
Cancer Treatment Research	93.395	Children's Hospital Of Philadelphia	3U10CA1808860227	(26,560)	-
Cancer Treatment Research	93.395	Children's Hospital Of Philadelphia	5R01CA21199602	601	-
Cancer Treatment Research	93.395	Children's Hospital Of Philadelphia	5U10CA18088604	(5,784)	-
Cancer Treatment Research	93.395	Children's Hospital Of Philadelphia	U10CA180886	7,228	-
Cancer Treatment Research	93.395	Children's Hospital Of Philadelphia	UM1CA097452	3,060	-
Cancer Treatment Research	93.395	Doseimaging	1R41CA20298001A1	(15)	-
Cancer Treatment Research	93.395	Duke University	5UM1CA18670405	227,330	-
Cancer Treatment Research	93.395	Duke University	5UM1CA1867070451	80,306	-
Cancer Treatment Research	93.395	Ecog-Acrin Medical Research Foundation	U10CA18082006	35,355	-
Cancer Treatment Research	93.395	Johns Hopkins University	5UM1CA13744309	26,965	-
Cancer Treatment Research	93.395	Massachusetts General Hospital	2U19CA02123939	327,196	-
Cancer Treatment Research	93.395	Massachusetts General Hospital	5U01NS9366302	241	-
Cancer Treatment Research	93.395	Medical Guidance Systems	1R41CA23302001A1	29,090	-
Cancer Treatment Research	93.395	NRG Oncology Foundation	1U10CA18086001	72,000	-
Cancer Treatment Research	93.395	NRG Oncology Foundation	1U10CA1808601	513	-
Cancer Treatment Research	93.395	NRG Oncology Foundation	2U10CA18086806	6,391	238
Cancer Treatment Research	93.395	NRG Oncology Foundation	5U10CA18086805	34	-
Cancer Treatment Research	93.395	NRG Oncology Foundation	U10CA180868	66,170	6,448
Cancer Treatment Research	93.395	Protexase	1R43CA24394101A1	77,750	-
Cancer Treatment Research	93.395	Sloan Kettering Institute	5R01CA18255105	6,389	-
Cancer Treatment Research	93.395	University of Alabama, Birmingham	08UCA189823A	6	-
Cancer Treatment Research	93.395	University of California, Irvine	5R24EY02728304	95,176	-
Cancer Treatment Research	93.395	University of California, Los Angeles	1568GTA552	(3,973)	-
Cancer Treatment Research	93.395	University of California, Los Angeles	2UM1CA12194709	(37,149)	-
Cancer Treatment Research	93.395	University of California, Los Angeles	UMCA121947	108,286	-
Cancer Treatment Research	93.395	University of Minnesota	5P01CA11141214	19,325	-
Cancer Treatment Research	93.395	University of Rochester	1R01CA21489001A1	27,939	-
Cancer Treatment Research	93.395	University of Texas M.D. Anderson	1R01CA23562201	107,390	-
Cancer Treatment Research	93.395	Vanderbilt University	5R01CA21404304	1,312	-
Cancer Treatment Research	93.395	Wake Forest University	UG1CA189824	21,000	-
Cancer Biology Research	93.396			6,222,158	90,474
Cancer Biology Research	93.396	Dana-Farber Cancer Institute	5R01CA13098809	16,766	-
Cancer Biology Research	93.396	Nupeak Therapeutics	1R41CA23594301	18,756	-
Cancer Biology Research	93.396	University of Iowa	5R01CA17474306	(19)	-
Cancer Biology Research	93.396	University of North Carolina, Chapel Hill	1R01CA244236-01	9,954	-
Cancer Biology Research	93.396	University of Virginia	5R21CA21272604	15,974	-
Cancer Biology Research	93.396	University of Virginia	5R21CA23185303	17,819	-
Cancer Biology Research	93.396	University of Wisconsin	1R01CA18729901A1	13,552	-
Cancer Center Support Grants	93.397			11,138,592	725,290
Cancer Center Support Grants	93.397	Case Western Reserve University	5U54CA16306008	81,147	-
Cancer Center Support Grants	93.397	Case Western Reserve University	U54CA16306009	7,423	-
Cancer Center Support Grants	93.397	John Hopkins University	U54CA210173	87,916	-
Cancer Research Manpower	93.398			4,619,411	-
Cancer Control	93.399	Alliance for Center in Oncology Foundation	2UG1CA18982306	45,891	-
Cancer Control	93.399	Children's Hospital Of Philadelphia	2UG1CA1899506	2,173	-
Cardiovascular Diseases Research	93.837			21,351,948	1,152,887
Cardiovascular Diseases Research	93.837	APT Therapeutics	1R43HL14069901	108,558	-
Cardiovascular Diseases Research	93.837	Brigham & Women's Hospital	5P50HL11234905	10,078	-
Cardiovascular Diseases Research	93.837	Brigham & Women's Hospital	5U01HL13016304	20,541	-
Cardiovascular Diseases Research	93.837	Capella Imaging Llc	4R42HL13934202	341,975	-
Cardiovascular Diseases Research	93.837	Children's Hospital Of Philadelphia	5R01HL13154403	21,725	-
Cardiovascular Diseases Research	93.837	Children's Hospital Of Philadelphia	R01HL147616	1,600	-
Cardiovascular Diseases Research	93.837	Duke University	2938081	1,138	-
Cardiovascular Diseases Research	93.837	Duke University	U10HL084904	5,060	-

The accompanying notes are an integral are of this schedule.

Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2020

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Cardiovascular Diseases Research	93.837	Emory University	2R01HL12239206A1	28,396	-
Cardiovascular Diseases Research	93.837	Emory University	5U01HL128566	1,915	-
Cardiovascular Diseases Research	93.837	Emory University	5U01HL12856602	1,357	-
Cardiovascular Diseases Research	93.837	Etiometry Inc	2R44HL1173405	55,339	-
Cardiovascular Diseases Research	93.837	I-Cordis LLC	1R43HL14583301A1	42,339	-
Cardiovascular Diseases Research	93.837	Johns Hopkins University	2004688628	68,790	-
Cardiovascular Diseases Research	93.837	Johns Hopkins University	3R34HL1087560251	(13,386)	-
Cardiovascular Diseases Research	93.837	Johns Hopkins University	R34HL108756	(11,941)	-
Cardiovascular Diseases Research	93.837	Joslin Diabetes Center, Inc	7R01HL06777316	43,683	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	1R01HL13864601	90,495	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5U01HL12333603	103,487	-
Cardiovascular Diseases Research	93.837	Medical College of Wisconsin	5R01HL12558003	6,966	-
Cardiovascular Diseases Research	93.837	Medical College of Wisconsin	5R01HL12558004	63,698	-
Cardiovascular Diseases Research	93.837	National Marrow Donor Program	1U24HL138660	3,137	-
Cardiovascular Diseases Research	93.837	National Marrow Donor Program	4U10HL06929416	3,548	-
Cardiovascular Diseases Research	93.837	New England Research Institutes	1U24HL13569101	43,235	-
Cardiovascular Diseases Research	93.837	Northwestern University	5R01HL13694203	22,277	-
Cardiovascular Diseases Research	93.837	Ohio State University	4UH3HL14014402	6,215	-
Cardiovascular Diseases Research	93.837	Ohio State University	5R01HL12885703	37,647	-
Cardiovascular Diseases Research	93.837	Ohio State University	5R01HL12885704	82,814	-
Cardiovascular Diseases Research	93.837	Research Foundation For The State University of New York	5U01HL13155205	44,543	-
Cardiovascular Diseases Research	93.837	Rightcare Solutions, Inc	4R44HL12492303	(4,404)	-
Cardiovascular Diseases Research	93.837	Sentiar, Inc	5R44HL14089603	121,228	-
Cardiovascular Diseases Research	93.837	St. Louis University	5R01HL12542404	80,427	-
Cardiovascular Diseases Research	93.837	University of Alabama	5P2CHD08685104	34,994	-
Cardiovascular Diseases Research	93.837	University of Alabama	5U01HL12033805	40,125	-
Cardiovascular Diseases Research	93.837	University of Alabama	5U01HL12033806	9,470	-
Cardiovascular Diseases Research	93.837	University of Alabama, Birmingham	1R01HL14914501	17,357	-
Cardiovascular Diseases Research	93.837	University of California, Davis	3UG3HL1418000251	15,462	-
Cardiovascular Diseases Research	93.837	University of California, Davis	4UG3HL14180003	660,657	-
Cardiovascular Diseases Research	93.837	University of California, Davis	5UG3HL14180002	48,059	-
Cardiovascular Diseases Research	93.837	University of California, San Diego	5R25HL14581702	15,813	-
Cardiovascular Diseases Research	93.837	University of Chicago	5R01HL12689204	30,077	-
Cardiovascular Diseases Research	93.837	University of Florida	1R01HL13675901A1	45,613	-
Cardiovascular Diseases Research	93.837	University of Pennsylvania	1R34HL14692701	7,103	-
Cardiovascular Diseases Research	93.837	University of Pennsylvania	5R01HL13490503	19,612	-
Cardiovascular Diseases Research	93.837	University of Pennsylvania	5R01HL13490504	8,057	-
Cardiovascular Diseases Research	93.837	University of Rochester	5R34HL13352602	6,181	-
Cardiovascular Diseases Research	93.837	Versiti Wisconsin Inc	1P01HL14445701	132,229	-
Cardiovascular Diseases Research	93.837	Versiti Wisconsin Inc	2R01HL06883513	41,684	-
Cardiovascular Diseases Research	93.837	Versiti Wisconsin Inc	5R01HL06883514	12,634	-
Cardiovascular Diseases Research	93.837	Wayne State University	5R01HL10909005	(2,246)	-
Cardiovascular Diseases Research	93.837	Yale University	5U01HL12551103	4,697	-
Lung Diseases Research	93.838			6,469,757	630,620
Lung Diseases Research	93.838	Brigham & Women's Hospital	5P01HL13282502	(26,113)	-
Lung Diseases Research	93.838	Children's Hospital of Philadelphia	5U01HL13474503	(7)	-
Lung Diseases Research	93.838	Children's Hospital of Philadelphia	5U01HL13474504	26,654	-
Lung Diseases Research	93.838	Children's Hospital of Philadelphia	U01HL134745	598	-
Lung Diseases Research	93.838	Johns Hopkins University	UM1HL134590	126,970	-
Lung Diseases Research	93.838	Massachusetts General Hospital	1UG3HL14017701A1	5,616	-
Lung Diseases Research	93.838	Nupeak Therapeutics	1R41HL14952301	80,442	-
Lung Diseases Research	93.838	Seattle Children's Hospital	1U01HL11462301A1	3,362	-
Lung Diseases Research	93.838	University of Arizona	5U01HL13004503	770,087	-
Lung Diseases Research	93.838	University of Kansas Medical Center	UG1HL139119	29,403	-
Lung Diseases Research	93.838	University of North Carolina at Chapel Hill	5U24HL13899803	2,822	-
Lung Diseases Research	93.838	University of North Carolina at Chapel Hill	2U54HL09645816	88,307	-
Lung Diseases Research	93.838	University of North Carolina at Chapel Hill	5U54HL09645815	6,093	-
Lung Diseases Research	93.838	University of Pittsburgh	5U01HL1995204	5,612	-
Lung Diseases Research	93.838	University Of Texas Health Science Center At Houston	R01HL145025	17,698	-
Blood Diseases and Resources Research	93.839			9,180,687	435,525
Blood Diseases and Resources Research	93.839	Augusta University	2R25HL10636510	5,293	-
Blood Diseases and Resources Research	93.839	Dana-Farber Cancer Institute	4P50HL11079005	32,419	-

The accompanying notes are an integral are of this schedule.

Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2020

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Blood Diseases and Resources Research	93.839	Emory University	1R01HL14379402	83,374	-
Blood Diseases and Resources Research	93.839	Johns Hopkins University	5R01HL13954303	10,445	-
Blood Diseases and Resources Research	93.839	Kalocyte	5R42HL13596503	192,288	-
Blood Diseases and Resources Research	93.839	Medical College of Wisconsin	1U01HL14347701	17,137	-
Blood Diseases and Resources Research	93.839	Medical University of South Carolina	5R01HL13389601A102R	(9,095)	-
Blood Diseases and Resources Research	93.839	National Marrow Donor Program	5U24HL13866002	21,961	-
Blood Diseases and Resources Research	93.839	National Marrow Donor Program	5U24HL13866002	3,473	-
Blood Diseases and Resources Research	93.839	Rutgers University	5U01HL13381703	(9,711)	-
Blood Diseases and Resources Research	93.839	Rutgers University	5U01HL13381704	11,210	-
Blood Diseases and Resources Research	93.839	St. Jude Children's Research Institute	5U01HL13399604	59,381	-
Blood Diseases and Resources Research	93.839	University of Alabama	7R01HL13389603	8,911	-
Blood Diseases and Resources Research	93.839	University of North Carolina at Chapel Hill	3U54HI0964581551	1,215	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840			833,460	552,370
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840	RASD Rwanda	1U24HL13979002	41,529	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846			12,882,091	375,954
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Boston University	1R01AR07442801A1	17,765	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brigham & Women's Hospital	5U01AR06804305	14,598	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Children's Hospital of Philadelphia	1U19AR06952501	671	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Cleveland Clinic	R01AR07413101	860	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Columbia University	1R21AR07600801	31,954	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Columbia University	5R01AR05783608	99,849	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Columbia University	5R01AR062947407	219,708	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Massachusetts General Hospital	1R01AR07601301	26,999	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Northwestern University	1U19AR06952601	9,365	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	St. Louis College Of Pharmacy	7R01AR06928003	2,696	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	St. Louis University	5R01AR06843803	(78)	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Steadman Philippon Research Institute	7R21AR07287003	54,653	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pennsylvania	5R01AR06906203	6,431	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pennsylvania	5R01AR06906204	35,956	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pennsylvania	5R01AR07087303	23,971	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pittsburgh	1R21AR07524201	74,067	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pittsburgh	1R56AR07614601	120,388	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pittsburgh	R01AR076146	18,237	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Southern California	5R01AR07221203	187,727	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Vanderbilt University	7R01AR06084607	194,431	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847			39,737,681	3,222,519
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Augusta University	5U24DK11525503	120,308	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Baylor Research Institute	1R21DK11136902	68,927	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Bioio LLC	1R42DK12165201A1	79,661	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Boston University	1R01DK10150101	24,224	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Brigham & Women's Hospital	5U01DK10430805	(9)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	California Institute Of Technology	5R01DK07893808	(11)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Case Western Reserve University	2U01DK09415707	(3,395)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Case Western Reserve University	5U01DK09415708	3,395	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Case Western Reserve University	5U01DK09415709	161,586	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Case Western Reserve University	DK11481201	20,105	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Cedars-Sinai Medical Center	3U01DK06241317	2,430	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Cedars-Sinai Medical Center	3U01DK0624131851	76,528	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Mercy Hospital	2U01DK06614317	9,449	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Mercy Hospital	5U01DK06614315	(1,488)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Mercy Hospital	U01DK066143	(26,232)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	5U01DK061230	95,971	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	5U01DK06123014	(38)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	5U01DK06123015	(114)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	5U01DK09824607	17,383	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	5U01DK09824608	163,379	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Icahn School of Medicine Mt. Sinai	5U24DK06242919	9,145	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Icahn School of Medicine Mt. Sinai	5U24DK06242920	58,719	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center, Inc	2UC4DK10110802	75	-

The accompanying notes are an integral are of this schedule.

Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2020

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center, Inc	7R01DK06498916	52,592	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Louisiana State University	3P30DK0724761351	10,000	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	5R01DK10135405	20,218	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Mcgill University	5R01DK11073703	13,954	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Medical University of South Carolina	1U01DK10483302	17,996	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Medical University of South Carolina	5U01DK10483304	(21,211)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Nationwide Children's Hospital	2U01DK10086607	16,652	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Nationwide Children's Hospital	SUM1DK10086605	(29,983)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northwestern University	2R01DK09221404A1	90,713	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Platform STL	1R41DK12025301	72,350	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Remd Biotherapeutics, Inc.	4R42DK10830503	145,622	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Senseion	R43DK12159801	44,847	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	St. Louis University	1R01DK11040603	188,332	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	St. Louis University	5U01DK08287112	49,401	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	State University of New York	5R01DK11045602	98	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	State University of New York at Buffalo	1R01DK11448502	50,204	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of California, San Diego	SUG3DK11493302	7,257	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of California, San Diego	UH3DK114933	234,582	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of California, San Francisco	1R01DK11598701	5,379	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of California, San Francisco	5R01DK11598702	37,169	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Chicago	1U54DK11861201	11,348	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Chicago	5P01DK05678818	8,697	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Chicago	5U54DK118621202	43,965	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Houston	R21DK113525	37,801	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Illinois	1R01DK11308001A1	27,708	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Iowa	3U01DK10833404S1	8,154	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Iowa	3U01DK10833405S1	29,730	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Iowa	5R01DK11875202	58,981	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Iowa	5U01DK10832802	2,435	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Iowa	5U01DK10832804S1	890	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Michigan	5R01DK106621005	26,923	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Michigan	5R01DK10790403	28,250	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Michigan	5U01DK06237016	20,476	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pennsylvania	1R01DK11843101	39,489	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pennsylvania	2U01DK10322506	42,882	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Pennsylvania	5U01DK10322505	13,194	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Rochester	1R01DK12068001A1	2,894	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Southern California	3U01DK10735004	148,452	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Virginia	5R01DK11186103	206,743	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Wisconsin, Madison	1R01DK11814501A1	169,998	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Vanderbilt University	1R01DK11921201	14,567	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Virginia Commonwealth University	5R01DK09481802	(4,132)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Virginia Commonwealth University	5R01DK09481805	8,038	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853			37,855,052	2,715,099
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853			106,130	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Boston University	5U01NS09333404	18,365	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Boston University	5U01NS09333405	13,522	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	California Institute Of Technology	R01NS102279	649	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Research Institute	1R01NS11229402	31,529	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children'S Research Institute	7U01NS10768105	(16,309)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Cincinnati Children's Hospital Medical Center	5R01NS06280609	68,723	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Cincinnati Children's Hospital Medical Center	5R01NS09605304	(2,819)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Collaborations Pharmaceuticals	1R43NS10707901	53,606	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Columbia University	1R211NS11306301	74,792	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Cornell University	5U54NS10071704	3,240	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Cornell University	7U54NS10071703	1,681	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Duke University	1R01NS11158801A1	37,770	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Duke University	5R01NS11158802	4,504	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Emory University	5U54TR00145608	(36,068)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Emory University	9U54NS11602509	176,831	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Johns Hopkins University	1R01NS10629201A1	1,096	-

The accompanying notes are an integral are of this schedule.

Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2020

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Kennedy Krieger	5K12NS09848204	146,321	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	LA Biomedical Research Institute	4R33NS09604403	46,358	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	LA Biomedical Research Institute	5R01NS10081503	20,577	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	LA Biomedical Research Institute	5R01NS10227902	34,891	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	1U01NS09025901A1	1,254	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	4U44NS09061602	3,811	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	U01NS096767	67,754	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	U01NS095388	11,894	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mitochondria in Motion	1R41NS11364201	55,498	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mitochondria in Motion	1R41NS11518401	56,029	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mount Sinai School Of Medicine	5R01NS09952703	61,610	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Oregon Health And Science University	1R01NS11194801A1	122,653	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Phoenix Nest, Inc.	2R44NS08906104	106,448	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Rutgers University	5U24MS09591404	160,199	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Seattle Children's Hospital	5R01NS09597903	47,406	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Francisco	5R01NS094292	33,537	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Francisco	5U01NS09276403	67,187	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Francisco	5U54NS09208903	555	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Francisco	R01NS094292	43,110	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Francisco	U01NS092764	1,879	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS09904301A1	18,551	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS10069901A1	7,669	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	5U01NS09586902	18,366	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	7U01NS10235302	2,274	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Connecticut	R01NS102633	89,277	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pennsylvania	1U19NS11045601A1	289,078	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pittsburgh	5R01NS0967140	1,963	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Southern California	2R01NS03446721	18,571	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Texas Austin	7R01NS09061703	16,798	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Texas Health Science Center At Houston	1R61NS11332901	6,953	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Virginia	5R01NS09965302	632	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Virginia	5U01NS08803405	2,838	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Washington	5R01NS09161803	42,917	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Vanderbilt University	1UG3NS11621801	228,878	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Wayne State University	5R01NS09457003	71,797	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Yale University	1R01NS11102901A1	10,678	-
Allergy and Infectious Diseases Research	93.855			48,736,775	8,583,916
Allergy and Infectious Diseases Research	93.855			74,891	-
Allergy and Infectious Diseases Research	93.855			1,458	-
Allergy and Infectious Diseases Research	93.855			116,251	-
COVID19-Allergy and Infectious Diseases Research	93.855			1,835	-
Allergy and Infectious Diseases Research	93.855	Albert Einstein College of Medicine	5R21AI12809002	(62)	-
Allergy and Infectious Diseases Research	93.855	Arrevas	1R41AI14078201	28,785	-
Allergy and Infectious Diseases Research	93.855	Boston Children's Hospital	5U01AI12661403	112	-
Allergy and Infectious Diseases Research	93.855	Boston Children's Hospital	5U01AI12661404	130,741	-
Allergy and Infectious Diseases Research	93.855	Brigham & Women's Hospital	5UM1AI06863612	(65,217)	-
Allergy and Infectious Diseases Research	93.855	Brigham & Women's Hospital	5UM1AI06863613	(97,247)	-
Allergy and Infectious Diseases Research	93.855	Case Western Reserve University	1R21AI13989801A1	44,347	-
Allergy and Infectious Diseases Research	93.855	Case Western Reserve University	5R01AI2520204	118,025	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital of Philadelphia	5R01AI13023102	120,205	-
Allergy and Infectious Diseases Research	93.855	Drexel University	5U19AI12891002	44,924	-
Allergy and Infectious Diseases Research	93.855	Drexel University	5U19AI12891003	99,327	-
Allergy and Infectious Diseases Research	93.855	Duke University	5UM1AI10468106	18,678	-
Allergy and Infectious Diseases Research	93.855	Fimbrion	1R43AI14983301	7,598	-
Allergy and Infectious Diseases Research	93.855	George Washington University	5R01AI12343304	14,218	-
Allergy and Infectious Diseases Research	93.855	Georgia State University	5U19AI10944505	110,613	-
Allergy and Infectious Diseases Research	93.855	Georgia State University	5U19AI10966405	39,711	-
Allergy and Infectious Diseases Research	93.855	Icahn School Of Medicine Mt. Sinai	HHSN272201400008C	447,682	-
COVID19-Allergy and Infectious Diseases Research	93.855	Icahn School Of Medicine Mt. Sinai	HHSN272201400008C	69,491	-
Allergy and Infectious Diseases Research	93.855	Icbiome, Inc	1R43AI14799101	47,644	-
Allergy and Infectious Diseases Research	93.855	Jackson Laboratory	1U19AI14273301	91,935	-

The accompanying notes are an integral are of this schedule.

Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2020

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Allergy and Infectious Diseases Research	93.855	Jackson Laboratory	5U19A114273302	63,232	-
Allergy and Infectious Diseases Research	93.855	La Jolla Institute	1U19A114279001	531,120	-
Allergy and Infectious Diseases Research	93.855	La Jolla Institute	1U19A114279001	295,690	-
Allergy and Infectious Diseases Research	93.855	La Jolla Institute	5U19A114279002	3,025	-
Allergy and Infectious Diseases Research	93.855	Michigan State University	5U01A1126610	5,543	-
Allergy and Infectious Diseases Research	93.855	Michigan State University	5U01A112661002	(1,333)	-
Allergy and Infectious Diseases Research	93.855	Mount Sinai School of Medicine	5U01A106359415	11,713	-
Allergy and Infectious Diseases Research	93.855	Mount Sinai School of Medicine	5U01A106359416	63,082	-
Allergy and Infectious Diseases Research	93.855	Nanocomposix	1R1A114787501	56,160	-
Allergy and Infectious Diseases Research	93.855	Newventureiq, Llc	1R41A114291901	52,533	-
Allergy and Infectious Diseases Research	93.855	Northwestern University	5P30A111794305	15,257	-
Allergy and Infectious Diseases Research	93.855	Oregon Health And Science University	5R01A113218602	175,466	-
Allergy and Infectious Diseases Research	93.855	Salk Institute	2R01A110140005	206,384	-
Allergy and Infectious Diseases Research	93.855	Salk Institute	5R01A110140006	425,786	-
Allergy and Infectious Diseases Research	93.855	San Jose State University	1R15A113814601A1	21,911	-
Allergy and Infectious Diseases Research	93.855	St. Jude Children's Research Institute	1U01A14461601	78,375	-
Allergy and Infectious Diseases Research	93.855	St. Jude Children's Research Institute	5U01A114461602	13,220	-
COVID19-Allergy and Infectious Diseases Research	93.855	St. Jude Children's Research Institute	3U01A114461602S1	48,710	-
Allergy and Infectious Diseases Research	93.855	The Benaroya Research Institute	5UM1A110956506	6,650	-
Allergy and Infectious Diseases Research	93.855	The George Washington University	1R21A113777102	16,939	-
Allergy and Infectious Diseases Research	93.855	University of Alabama	1U19A114275901	225,284	-
Allergy and Infectious Diseases Research	93.855	University of Alabama	1U19A114275902	87,019	-
Allergy and Infectious Diseases Research	93.855	University of Arizona	5R01A1099108	14,857	-
Allergy and Infectious Diseases Research	93.855	University of Arizona	5R01A112994503	26,079	-
Allergy and Infectious Diseases Research	93.855	University of Calgary	R34A1136783	20,487	-
Allergy and Infectious Diseases Research	93.855	University of California, Berkeley	5P01A10669505	74,760	-
Allergy and Infectious Diseases Research	93.855	University of California, Berkeley	5P01A10669504	942	-
Allergy and Infectious Diseases Research	93.855	University of California, Los Angeles	1U01A11640001A1	6,701	-
Allergy and Infectious Diseases Research	93.855	University of California, Los Angeles	5U01A11640002	249,306	-
Allergy and Infectious Diseases Research	93.855	University of California, Los Angeles	5UM1A106863614	17,256	-
Allergy and Infectious Diseases Research	93.855	University of California, Los Angeles	7UM1A106863613	308,201	-
Allergy and Infectious Diseases Research	93.855	University of California, San Francisco	5U54A18297309	173	-
Allergy and Infectious Diseases Research	93.855	University of Chicago	5R01A112777403	210,886	-
Allergy and Infectious Diseases Research	93.855	University of Colorado	5R01A106252014	24,493	-
Allergy and Infectious Diseases Research	93.855	University of Colorado, Denver	5R01A114143602	152,312	-
Allergy and Infectious Diseases Research	93.855	University of Florida	1R01A114147801	134,496	-
Allergy and Infectious Diseases Research	93.855	University of Kentucky	1R01A114075802	229,322	-
Allergy and Infectious Diseases Research	93.855	University of Louisville	1R01A13967101A1	105,671	-
Allergy and Infectious Diseases Research	93.855	University of Michigan	5R01A111262605	133,762	-
Allergy and Infectious Diseases Research	93.855	University of Mississippi	1R21A114221001A1	20,752	-
Allergy and Infectious Diseases Research	93.855	University of North Carolina at Chapel Hill	5U19A110996505	76,034	-
Allergy and Infectious Diseases Research	93.855	University of Pennsylvania	1R01A114053902	224,456	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh	1R01A114266202	26,981	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh	1R01A114582801	149,560	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh	1R01A115021401	15,353	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh	5R01A112334807	208,958	-
Allergy and Infectious Diseases Research	93.855	University of Texas Austin	1R21A112950501	32,976	-
Allergy and Infectious Diseases Research	93.855	University of Texas Austin	5R21A112950502	18,553	-
Allergy and Infectious Diseases Research	93.855	University of Texas Medical Branch at Galveston	1R01A114635301	117,750	-
Allergy and Infectious Diseases Research	93.855	University of Texas Southwestern Medical Center	1U19A114278401	509,994	-
Allergy and Infectious Diseases Research	93.855	University of Texas Southwestern Medical Center	5U19A114278402	210,699	-
Allergy and Infectious Diseases Research	93.855	University of Texas Southwestern Medical Center	U19A114278401	57,908	-
Allergy and Infectious Diseases Research	93.855	University of Washington	1R01A11459601	207,754	-
Allergy and Infectious Diseases Research	93.855	University of Washington	5R01A11459601	90,079	-
Allergy and Infectious Diseases Research	93.855	University of Washington, Seattle	5R01A110400205	24,490	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin, Madison	1R01A113251901A1	33,072	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin, Madison	1R01A113864701A1	28,443	-
COVID19-Allergy and Infectious Diseases Research	93.855	University of Wisconsin, Madison	3UM1A111427106S1	31,917	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin, Madison	5P01A113213202	73,638	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin, Madison	5U19A110677205	(711)	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin, Madison	5UM1A111427103	(320)	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin, Madison	5UM1A111427105	106,703	-

The accompanying notes are an integral are of this schedule.

Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2020

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Allergy and Infectious Diseases Research	93.855	University of Wisconsin, Madison	SUM1AI11427106	610,147	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University	1UM1AI4845201	9,436	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University	5R01AI11481606	138,738	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University	5U01AI10433606	(291)	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	501AI12782804	332,659	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	5UM1AI06861912	547,763	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	5UM1AI0693915	68,232	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	5UM1AI06943914	502,465	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	5UM1AI06943915	514,885	-
Allergy and Infectious Diseases Research	93.855	Vaxnewmo	1R41AI13623301	36,119	-
Biomedical Research and Research Training	93.859			25,872,030	436,936
Biomedical Research and Research Training	93.859	Arch Innotek, LLC	1R41GM13027701	14,231	-
Biomedical Research and Research Training	93.859	Cell Microsystems, Inc	1R41GM13147501	53,518	-
Biomedical Research and Research Training	93.859	Cell Microsystems, Inc	5R44GM11988803	22,188	-
Biomedical Research and Research Training	93.859	Drug Design Methodologies	1R43GM12657901	(5,469)	-
Biomedical Research and Research Training	93.859	Jackson Laboratory	5R01GM12573602	67,832	-
Biomedical Research and Research Training	93.859	Nationwide Children'S Hospital	5R01GM09420305	(528)	-
Biomedical Research and Research Training	93.859	Nawgen, Llc	1R41GM12668201A1	65,468	-
Biomedical Research and Research Training	93.859	Protein Metrics	2R42GM12113302	46,314	-
Biomedical Research and Research Training	93.859	Radiologics	1R44GM12543801	19,221	-
Biomedical Research and Research Training	93.859	St. Louis University	1R01GM134081	12,529	-
Biomedical Research and Research Training	93.859	University of Alabama	1R25GM13051701	66,815	-
Biomedical Research and Research Training	93.859	University of Colorado, Denver	5R01GM12374603	37,050	-
Biomedical Research and Research Training	93.859	University of Illinois	7R01GM11458805	66,975	-
Biomedical Research and Research Training	93.859	University of Michigan	5R01GM12243404	48,406	-
Biomedical Research and Research Training	93.859	University of Michigan	5U54GM10329707	14,483	-
Biomedical Research and Research Training	93.859	University of Michigan	8U54AI15047008	178,563	-
Biomedical Research and Research Training	93.859	University of North Carolina, Chapel Hill	1R01GM13728601	4,122	-
Biomedical Research and Research Training	93.859	University of Pittsburgh	2R01GM10861805	68,571	-
Biomedical Research and Research Training	93.859	University of Texas, Austin	5R01GM11423704	(55,929)	-
Biomedical Research and Research Training	93.859	University of Wisconsin, Madison	5P41GM10853804	1,420	-
Biomedical Research and Research Training	93.859	Vanderbilt University	2R01GM11661605	34,151	-
Child Health and Human Development Extramural Research	93.865			15,613,313	2,516,243
Child Health and Human Development Extramural Research	93.865	Boston Medical Center	1R01HD09506001A1	34,696	-
Child Health and Human Development Extramural Research	93.865	Boston University	5R01HD091130	33,142	-
Child Health and Human Development Extramural Research	93.865	Boston University	5R01HD09244402	211,988	-
Child Health and Human Development Extramural Research	93.865	Boston University	5R01HD7281506A1	35,411	-
Child Health and Human Development Extramural Research	93.865	Children'S Medical Health Center	7R01HD07191506	1,804	-
Child Health and Human Development Extramural Research	93.865	Cincinnati Children'S Hospital Medical Center	5R01HD08601103	(220)	-
Child Health and Human Development Extramural Research	93.865	Cincinnati Children'S Hospital Medical Center	5R01HD08601104	41,811	-
Child Health and Human Development Extramural Research	93.865	Columbia University	5R01HD09100303	18,983	-
Child Health and Human Development Extramural Research	93.865	Lurie Childrens Hospital	1R21HD09640201A1	19,513	-
Child Health and Human Development Extramural Research	93.865	Nationwide Children's Hospital	1R01HD09134701A1	2,773	-
Child Health and Human Development Extramural Research	93.865	Nationwide Children's Hospital	1R01HD09597601A1	5,099	-
Child Health and Human Development Extramural Research	93.865	Nationwide Children's Hospital	5R01HD09134702	33,073	-
Child Health and Human Development Extramural Research	93.865	Nemours Children'S Clinic	5R01HD07846303	11,617	-
Child Health and Human Development Extramural Research	93.865	Nemours Children'S Clinic	5R01HD07846305	29,660	-
Child Health and Human Development Extramural Research	93.865	Newventureiq, Llc	1R41HD09783301	36,970	-
Child Health and Human Development Extramural Research	93.865	Oklahoma State University	2R01HD07457909	9,719	-
Child Health and Human Development Extramural Research	93.865	Oklahoma State University	2R01HD07457910	4,858	-
Child Health and Human Development Extramural Research	93.865	Oregon Health And Science University	1U24HD10098201	20,453	-
Child Health and Human Development Extramural Research	93.865	Oregon Health And Science University	7R01HD07864106	95,494	-
Child Health and Human Development Extramural Research	93.865	Pennsylvania State University	5DP1HD08607105	2,458	-
Child Health and Human Development Extramural Research	93.865	Research Foundation For The State University Of New York	5R01HD08029205	186,267	-
Child Health and Human Development Extramural Research	93.865	St. Louis College Of Pharmacy	1R61HD09974801	45,386	-
Child Health and Human Development Extramural Research	93.865	University Of Alabama	1R13HD10212801	575	-
Child Health and Human Development Extramural Research	93.865	University Of Alabama	5K01HD07958204	602	-
Child Health and Human Development Extramural Research	93.865	University Of California, Los Angeles	5R01HD09247103	8,445	-
Child Health and Human Development Extramural Research	93.865	University Of California, Los Angeles	5R01HS09247103	1,438	-
Child Health and Human Development Extramural Research	93.865	University Of California, San Francisco	5R01HD09241902	32,324	-
Child Health and Human Development Extramural Research	93.865	University of Chicago	1R01HD09984701	10,582	-
Child Health and Human Development Extramural Research	93.865	University of Colorado	1R01HD09799001A1	19,311	-

The accompanying notes are an integral are of this schedule.

Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2020

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Child Health and Human Development Extramural Research	93.865	University Of Indiana	7R01HD08600704	104,797	-
Child Health and Human Development Extramural Research	93.865	University Of Massachussets Amherst	1R01HD09249902	7,885	-
Child Health and Human Development Extramural Research	93.865	University Of Michigan	7R01HD08523303	(38)	-
Child Health and Human Development Extramural Research	93.865	University Of North Carolina At Chapel Hill	5R01HD05574113	431,849	-
Child Health and Human Development Extramural Research	93.865	University Of Southern California	5R01HD08134605	11,750	-
Child Health and Human Development Extramural Research	93.865	University Of Texas Austin	7U01HD07738406	216,075	-
Child Health and Human Development Extramural Research	93.865	University Of Texas Health Science Center At Houston	1R01HD09766901	40,439	-
Child Health and Human Development Extramural Research	93.865	University Of Texas Medical Branch at Galveston	5P2CHD06570210	11,104	-
Child Health and Human Development Extramural Research	93.865	University Of Texas Southwestern Medical Center	5P01HD08438704	410,040	-
Child Health and Human Development Extramural Research	93.865	University Of Virginia	5R01HD07207105	129,521	-
Child Health and Human Development Extramural Research	93.865	University Of Wisconsin-Madison	1R01HD08300101A1	146,238	-
Child Health and Human Development Extramural Research	93.865	Yale University	5R21HD08913102	5,559	-
Child Health and Human Development Extramural Research	93.865	Yale University	5R21HD08913105	1,271	-
Child Health and Human Development Extramural Research	93.865	Yale University	5U01HD05592510	40	-
Aging Research	93.866			66,361,513	10,598,841
Aging Research	93.866	Clear	1R43AG065075-01A1	12,416	-
Aging Research	93.866	Cognition Therapeutics, Inc	1RF1AG05778001	35,394	-
Aging Research	93.866	Columbia University	3U01AG02374913S1	(987)	-
Aging Research	93.866	Columbia University	5U24AG0562702	1,853	-
Aging Research	93.866	Columbia University	5U24AG0562703	75,044	-
Aging Research	93.866	Columbia University	5U24UA5627004	2,544	-
Aging Research	93.866	Duke University	2037606	7,047	-
Aging Research	93.866	Duke University	R24AG054355	27,047	-
Aging Research	93.866	Harvard School of Public Health	1R01AG06093501	180,337	-
Aging Research	93.866	Hebrew Rehabilitation Center	5R24AG05425904	17,457	-
Aging Research	93.866	Hebrew Rehabilitation Center	R24AG054259-04S1	7,423	-
Aging Research	93.866	Icahn School Of Medicine Mt. Sinai	5U01AG05241103	(625)	-
Aging Research	93.866	Icahn School Of Medicine Mt. Sinai	5U24AG05241104	166,013	-
Aging Research	93.866	Indiana University	1U01AG05719501A1	94,516	-
Aging Research	93.866	Johns Hopkins University	1RF1AG05986901	44,290	-
Aging Research	93.866	Johns Hopkins University	RF1AG050745	5,820	-
Aging Research	93.866	Mayo Clinic	1U19AG06391101	19,945	-
Aging Research	93.866	Mayo Clinic	5U01AG04539004	(302)	-
Aging Research	93.866	Mayo Clinic	5U01AG04539005	30,458	-
Aging Research	93.866	NCIRE	U19AG024904	168,870	-
Aging Research	93.866	NCIRE	U19AG02490413	46,033	-
Aging Research	93.866	Northwestern University	3R01AG4741605S1	25,161	-
Aging Research	93.866	Northwestern University	5R01AG04741603	3,121	-
Aging Research	93.866	Ohio State University	R01AG05619	230,905	-
Aging Research	93.866	Parabon Nanolabs	5R44AG05036603	47,541	-
Aging Research	93.866	Pennsylvania State University	5U2CAG06040802	35,169	-
Aging Research	93.866	Pennsylvania State University	IU2CAG06040801	12,866	-
Aging Research	93.866	Regenerative Research Foundation	5R01AG05629303	61,178	-
Aging Research	93.866	St. Louis College Of Pharmacy	9RF1AG06076906A1	61,195	-
Aging Research	93.866	St. Louis University	5R01AG05871402	5,743	-
Aging Research	93.866	Sutter Bay	1R01AG05941601	65,387	-
Aging Research	93.866	University Of California, San Diego	5U01AG01048326	2,791	-
Aging Research	93.866	University Of California, San Diego	3U19AG010483-26S1	(483)	-
Aging Research	93.866	University Of California, San Diego	5U19AG01048326	2,027	-
Aging Research	93.866	University Of California, San Francisco	1P30AG06242201	5,195	-
Aging Research	93.866	University Of California, San Francisco	1RF1AG059009-01	75,897	-
Aging Research	93.866	University Of California, San Francisco	2R01AG03879106A1	9,119	-
Aging Research	93.866	University Of California, San Francisco	5R01AG04561105	(325)	-
Aging Research	93.866	University Of California, San Francisco	5R01AG06235902	113,429	-
Aging Research	93.866	University Of Kentucky	2R01AG03865106A1	16,612	-
Aging Research	93.866	University of Miami	1R01AG06461401	34,391	-
Aging Research	93.866	University of Missouri	R01AG059818	5,961	-
Aging Research	93.866	University Of Nevada Reno	3P01AG05144303S1	28,349	15,316
Aging Research	93.866	University Of Pennsylvania	5R01AG05443502	345,187	-
Aging Research	93.866	University Of Pittsburgh	1R01AG06049901	398,007	-
Aging Research	93.866	University Of Pittsburgh	1R56AG06487701	654,533	-
Aging Research	93.866	University Of Pittsburgh	5U01AG05140604	768	-

The accompanying notes are an integral are of this schedule.

Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2020

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Aging Research	93.866	University Of Pittsburgh	5U01AG05140605	411,238	-
Aging Research	93.866	University Of Pittsburgh	5U01AG5140605	10,041	-
Aging Research	93.866	University Of Southern California	1R01AG05379802	14,249	-
Aging Research	93.866	University Of Southern California	1R61AG06654301	2,977	-
Aging Research	93.866	University Of Southern California	2U19AG02490413	54,093	-
Aging Research	93.866	University Of Southern California	5P01AG05235002	237,752	-
Aging Research	93.866	University Of Southern California	5P01AG05235003	86,578	-
Aging Research	93.866	University Of Southern California	5U19AG01048325	5,648	-
Aging Research	93.866	University Of Southern California	5U24AG05743702	39,532	-
Aging Research	93.866	University Of Southern California	5U24AG05743703	60,770	-
Aging Research	93.866	University Of Texas Southwestern Medical Center	5R01AG04867805	88,866	-
Aging Research	93.866	University Of Texas Southwestern Medical Center	5R01AG04974904	386,763	-
Aging Research	93.866	University Of Washington	3U01AG0169762059	37,025	-
Aging Research	93.866	University Of Washington	5U01AG01697619	(900)	-
Aging Research	93.866	University Of Washington	5U01AG01697620	(2,125)	-
Vision Research	93.867			10,984,434	1,084,031
Vision Research	93.867	Boston University	5R21EY02759002	(67)	-
Vision Research	93.867	Duke University	1R21EY02938401	(5,375)	-
Vision Research	93.867	Duke University	5R01Y02500904	26,912	-
Vision Research	93.867	Duke University	5R21EY02938402	3,678	-
Vision Research	93.867	New York University School of Medicine	1U10EY02686901	1,037	-
Vision Research	93.867	University Of California, Irvine	5U01EY02545106	109,397	-
Vision Research	93.867	University Of California, San Diego	R21EY03112501	1,384	-
Vision Research	93.867	University Of Illinois	R21EY02761202	(12,221)	-
Vision Research	93.867	University Of Massachusetts	5R01EY02860202	127,161	-
Vision Research	93.867	University Of Michigan	5R01Y02664103	9,269	-
Vision Research	93.867	University of Missouri	1R21EY02910601A1	8	-
Medical Library Assistance	93.879			451,973	123,731
Medical Library Assistance	93.879	California Institute of Technology	5U01LM01267202	16,373	-
Medical Library Assistance	93.879	University of Arkansas	5R01LM01248202	16,286	-
Medical Library Assistance	93.879	University of Arkansas	5R01LM01248204	92,376	-
Global Health Research and Research Training	93.RD			40,187	6,414
Global Health Research and Research Training	93.989			20,262	-
Global Health Research and Research Training	93.989	Asociaion Benefica Prisma	1D71TW01120501	2,042	-
Global Health Research and Research Training	93.989	Regional Allicance for Sustainable Development (RASD) Rwanda	5D43TW01033504	114,151	-
Global Health Research and Research Training	93.989	Vanderbilt University Medical Center	5UM1A106861911	(1,952)	-
National Cancer Institute (NCI)	93.RD	Arvis Technologies LLC	HHSN261201500054C	(58,240)	-
National Cancer Institute (NCI)	93.RD	Brigham & Women's Hospital	3U10CA18082103	7,196	-
National Cancer Institute (NCI)	93.RD	Ecog-Acrin Medical Research Foundation	UNKNOWN	34,920	-
National Cancer Institute (NCI)	93.RD	Leidos Biomedical Research	75N91019D00024	3,389	-
National Cancer Institute (NCI)	93.RD	Leidos Biomedical Research	HHSN261200800001E	29,893	-
National Cancer Institute (NCI)	93.RD	Leidos Biomedical Research	HHSN261201500003I	143,822	-
National Cancer Institute (NCI)	93.RD	Massachusetts General Hospital	218211	(191)	-
National Cancer Institute (NCI)	93.RD	Massachusetts General Hospital	220778	162,892	-
National Cancer Institute (NCI)	93.RD	NRG Oncology Foundation	LPMO011	30,308	14,762
National Cancer Institute (NCI)	93.RD	Social & Scientific Systems Inc.	HHSN261200800001E	500	-
National Cancer Institute (NCI)	93.RD	Social & Scientific Systems Inc.	HHSN2722013000141	284	-
National Cancer Institute (NCI)	93.RD	Social & Scientific Systems Inc.	HHSN2722013000141	(284)	-
National Cancer Institute (NCI)	93.RD	Westat	6426510	20,428	-
National Heart, Lung and Blood Institute (NHLBI)	93.RD	University of Michigan	HHSN268201100026C	44,581	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD			1,087,943	234,055
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD			954,332	-
COVID19-National Institute of Allergy and Infectious Diseases (NIAID)	93.RD			23,086	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Albert Einstein College of Medicine	5R21A112809002	(1,973)	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Ichan School of Medicine at Mt. Sinai	75N93019C00051	259,823	-
COVID19-National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Ichan School of Medicine at Mt. Sinai	75N93019C00051	70,865	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Northwestern University	HHSN272201700060C	728,218	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Rutgers University	HHSN271201800023I	436,860	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	St. Jude Children's Research Institute	HHSN272201400006C	388,521	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	University of Alabama, Birmingham	HHSN272201100035C	(1,465)	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	University of Alabama, Birmingham	HHSN272201100037C	1,883	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	University of Alabama, Birmingham	HHSN272201600018C	4,171	-

The accompanying notes are an integral are of this schedule.

Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2020

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	University of Montana	HHSN272201400050C	125,661	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Vanderbilt University Medical Center	75N93019C000074	96,377	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Vanderbilt University Medical Center	HHSN272201300023I	57,609	-
National Institute of Biomedical Imaging and Bioengineering (NIBIB)	93.RD	Venturewell	C4028	25,001	-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	93.RD	Children's Mercy Hospital	SU01DK06614302	300	-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	93.RD	George Washington University	TRIALNET	18,706	-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	93.RD	Remd Biotherapeutics, Inc.	2R44DK108305	149,819	-
National Institute of Mental Health (NIMH)	93.RD	Northwestern University	1R01MH12187701	43,703	-
National Institute of Neurological Disorders and Stroke (NINDS)	93.RD	Emory University	9U54NS1162509	5,651	-
National Institute of Neurological Disorders and Stroke (NINDS)	93.RD	University of Alabama, Birmingham	SU01NS09259504	34,609	-
National Institute of Health Clinical Research Center	93.RD			8,361	-
National Institutes of Health (NIH)	93.RD	Case Western Reserve University	CTN801	7,294	-
National Institutes of Health (NIH)	93.RD	Duke University	HHSN275201000003I	78,824	-
National Institutes of Health (NIH)	93.RD	ICF Macro Inc.	HHSN26120140002B	34,134	-
National Institutes of Health (NIH)	93.RD	Johns Hopkins University	1U01HL15056801	3,470	-
National Institutes of Health (NIH)	93.RD	Mathmatica	HHSP233201500035I/HHSP233	19,220	-
National Institutes of Health (NIH)	93.RD	University of Iowa	400508191	7	-
Office of the Assistant Secretary for Administration					
Office of the Assistant Secretary for Administration	93.RD	American Institutes for Research	HHSP233201500032I	22,147	-
Substance Abuse and Mental Health Services Administration					
Projects of Regional and National Significance	93.243			80,278	-
Substance Abuse and Mental Health Services Administration	93.RD	St. Louis County	SAMHSA	19,123	-
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES				516,941,459	50,029,296
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION					
National Aeronautics and Space Administration					
Science	43.001			5,493,285	220,407
Science	43.001	Bay Area Environmental Research	NASA80NSSC18K1082	27,059	-
Science	43.001	Bay Area Environmental Research	NNX17AC02G	61,402	-
Science	43.001	Brown University	NNX16AG49G	6,513	-
Science	43.001	California Institute of Technology	80NSSC18K0223	86,596	-
Science	43.001	Cornell University	JPL1536058	4,716	-
Science	43.001	Jet Propulsion Laboratory	1628233	52,116	-
Science	43.001	Jet Propulsion Laboratory	1649883	14,625	-
Science	43.001	Johns Hopkins University	80NSSC17K0418	18,138	-
Science	43.001	Planetary Science Institute	80NSSC17K0343	18,639	-
Science	43.001	Rensselaer Polytechnic Institute	80NSSC19M0069	6,122	-
Science	43.001	Smithsonian Astrophysical Observatory	GO718018A	40,550	-
Science	43.001	Smithsonian Astrophysical Observatory	GO819022X	5,738	-
Science	43.001	Smithsonian Astrophysical Observatory	GO920047B	8,707	-
Science	43.001	Smithsonian Astrophysical Observatory	NAS803060	38,447	-
Science	43.001	University of New Mexico	80NSSC19K0958	36,121	-
Space Operations	43.007			245,524	-
Education	43.008	Missouri University of Science and Technology	NNX14AN17A	(19,697)	-
Education	43.008	Missouri University of Science and Technology	NNX15AK03H	64,498	-
Space Technology	43.012			188,147	-
NASA	43.RD	Arizona State University	NNG07EK00C	95,757	-
NASA	43.RD	Cornell University	JPL1536058	9,974	-
NASA	43.RD	Jet Propulsion Laboratory	NM0710630	35,254	-
NASA	43.RD	Jet Propulsion Laboratory	NM0710805	108,581	-
NASA	43.RD	Jet Propulsion Laboratory	NNN12AA01C	262,851	-
NASA	43.RD	Johns Hopkins University	1277793	149,973	-
NASA	43.RD	Southwest Research Institute	NASW02008	49,387	-
NASA	43.RD	Southwest Research Institute	NNN12AA01C	25,037	-
NASA	43.RD	University of Texas Austin	NNM16AA26C	13,219	-
TOTAL NATIONAL AERONAUTICS AND SPACE ADMINISTRATION				7,147,279	220,407

The accompanying notes are an integral are of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2020

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
NATIONAL SCIENCE FOUNDATION					
National Science Foundation					
Engineering Grants	47.RD	University of Utah	UNKNOWN	(852)	-
Engineering Grants	47.041			4,212,370	555,075
Engineering Grants	47.041	Thermoai Inc	1938485	67,545	-
Engineering Grants	47.041	University of Central Florida	1908167	21,321	-
Engineering Grants	47.041	University of Illinois	1900277	59,659	-
Engineering Grants	47.041	University of Pennsylvania	CMMI1548571	813,396	-
Engineering Grants	47.041	University of Texas at Austin	1710922	27,380	-
Engineering Grants	47.041	Wichita State University	1162819	13,280	-
Engineering Grants	47.041	Yale University	1542815	26,776	-
Mathematic and Physical Sciences	47.049			2,993,930	-
Mathematic and Physical Sciences	47.049	Barnard College	1828168	76,131	-
Mathematic and Physical Sciences	47.049	Oregon State University	1606982	(10,611)	-
Mathematic and Physical Sciences	47.049	University of Minnesota	CHE1413862	23,943	-
Mathematic and Physical Sciences	47.049	University of Minnesota	CHE1906135	171,842	-
Geosciences	47.050			1,248,711	31,833
Geosciences	47.050	Columbia University	OPP1743310	13,268	-
Geosciences	47.050	Cornell University	1654568	131,056	-
Computer and Information Science and Engineering	47.070			3,174,470	44,192
COVID19-Computer and Information Science and Engineering	47.070	Georgia Institute of Technology	IIS2027689	741	-
Computer and Information Science and Engineering	47.070	University of California, Berkely	NSF1640899	164,434	33,397
Computer and Information Science and Engineering	47.070	University of Texas at Austin	1550593	25,508	-
Computer and Information Science and Engineering	47.070	University of Utah	1564287	29,216	-
Computer and Information Science and Engineering	47.070	University of Utah	1622741	60,814	-
Computer and Information Science and Engineering	47.070	University of Utah	CNS182688	65,630	-
Computer and Information Science and Engineering	47.070	Virginia Polytech Institute	ACI4547580	32,188	-
Computer and Information Science and Engineering	47.070	Virginia Polytech Institute	CNS1837519	32,336	-
Biological Sciences	47.074			4,768,427	697,081
COVID19-Biological Sciences	47.074			47,613	-
Biological Sciences	47.074	University of Wisconsin, Madison	1818040	14,109	-
Biological Sciences	47.074	University of Wisconsin, Madison	1840687	272,689	-
Biological Sciences	47.074	University of Wisconsin, Madison	IOS-1339325	4,570	-
Social, Behavioral, and Economic Sciences	47.RD			144,830	-
Social, Behavioral, and Economic Sciences	47.075			381,624	17,160
Social, Behavioral, and Economic Sciences	47.075	Georgia State University	1740201	9,949	-
Social, Behavioral, and Economic Sciences	47.075	University of Texas at Austin	1638822	41,384	-
Education and Human Resources	47.076			2,279,765	-
Education and Human Resources	47.076	Business-Higher Education Forum	DUE1331063	95,827	-
Education and Human Resources	47.076	Harris-Stowe State University	1619639	116,666	-
Education and Human Resources	47.076	Indiana University	DUE1534014	9,945	-
Education and Human Resources	47.076	University of Alabama	1915544	12,852	-
Education and Human Resources	47.076	University of Wisconsin	1726625	27,155	-
Office of International Science and Engineering	47.079	CFDF Global	OISE9531011	4,553	-
Office of Integrative Activities	47.083	University of Missouri	OIA-1355406	67,714	-
TOTAL NATIONAL SCIENCE FOUNDATION				21,774,154	1,378,738
AGENCY FOR INTERNATIONAL DEVELOPMENT					
Agency for International Development					
Agency for International Development Foreign Assistance for Programs Overseas	98.001	CARE	720FDA19GR00221	97,292	-
Agency for International Development Foreign Assistance for Programs Overseas	98.001	Michigan State University	7200AA18LE0003	64,352	31,850
Agency for International Development Foreign Assistance for Programs Overseas	98.001	Task Force for Global Health	AIDOAA1400008	12,774	-
Agency for International Development	98.RD	Drugs for Neglected Diseases	AIDOAA1400010	84,654	-
Agency for International Development	98.RD	Mississippi State University	7200AA18CA00030	47,336	-
Agency for International Development	98.RD	Mississippi State University	NA160AR4320199	14,649	-
Agency for International Development	98.RD	National Academy of Sciences	ESPA00050000100	4,169	-
Agency for International Development	98.RD	Tufts University	AIDOAAC1600020	73,233	-
Agency for International Development	98.RD	University of Georgia	7200AA18CA00003	71,224	-
DEPARTMENT OF AGRICULTURE					
Agricultural Research Service					
Agricultural Research - Basic and Applied Research	10.RD	University of Hawaii	2020-67022-31146	1,953	-
National Institute of Food and Agriculture					
Biotechnology Risk Assessment Research	10.219			71,825	-
Agriculture and Food Research Initiative (AFRI)	10.310			49,140	-
DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT					
Department of Housing and Urban Development					
Office of Healthy Homes and Lead Hazard Control	14.906			205,104	7,600

The accompanying notes are an integral are of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2020

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
DEPARTMENT OF THE INTERIOR					
U.S. Geological Survey					
Research & Data Collection	15.808			2,595	-
DEPARTMENT OF JUSTICE					
Violence Against Women Office					
OVW Research and Evaluation Program	16.026			60,784	8,774
Department of Justice	16.123	City of St. Louis	18-51	16,197	-
Department of Justice	16.830	Annie Malone Children & Family Services	2016GJFXK006	3,732	-
DEPARTMENT OF TRANSPORTATION					
Federal Highway Administration					
National Highway Traffic Safety Administration	20.RD	Wake Forest University	DTNH2217D00070	15,350	-
DEPARTMENT OF THE TREASURY					
Bureau of Consumer Financial Protection	21.RD			21,455	-
Bureau of Consumer Financial Protection	21.RD	ABT Associates	49852	1,710	-
Bureau of Consumer Financial Protection	21.RD	ABT Associates	GS00F252CA	895	-
DEPARTMENT OF VETERANS AFFAIRS					
Department of Veterans Affairs	64.RD			70,336	-
Department of Veterans Affairs	64.RD			(13)	-
Department of Veterans Affairs	64.RD			5	-
Department of Veterans Affairs	64.RD			13,715	-
Department of Veterans Affairs	64.RD			42,897	-
ENVIRONMENTAL PROTECTION AGENCY					
Office of Research and Development					
Environmental Protection Agency	66.RD	Applied Energy Group	01313134000	34,264	-
Environmental Protection Agency	66.RD	Aptim	68HERC19D0009	30,818	-
Environmental Protection Agency	66.RD	Aptim	EPC14012	10	-
NATIONAL ENDOWMENT FOR THE HUMANITIES					
Promotion of the Humanities - Fellowships and Stipends	45.160			190,799	-
Promotion of the Humanities - Office of Digital Humanities	45.169	University of Maine	HAA26129018	14,707	-
Total Research & Development Cluster				570,421,650	54,216,100
Other Sponsored Programs					
AGENCY FOR INTERNATIONAL DEVELOPMENT					
Foreign Assistance to American Schools and Hospitals Abroad	98.006			220,000	-
DEPARTMENT OF DEFENSE					
U.S. Army Material Command					
Basic Scientific Research	12.431			42,491	-
DEPARTMENT OF HEALTH AND HUMAN SERVICES					
Administration for Children and Families					
Affordable Care Act Personal Responsibility Education Program	93.092			100,062	7,795
Administration for Community Living					
Alzheimer's Initiative	93.763	Memory Home Care Solutions	90ADPI00210100	17,625	-
Centers for Disease Control					
Autism and Other Developmental Disabilities	93.998			206,845	-
Autism and Other Developmental Disabilities	93.998			183,985	-
Assistance Programs for Chronic Disease Prevention and Control	93.945	Missouri Department of Health and Human Services	DH1716A0006	49,750	-
Birth Defects and Developmental Disabilities - Prevention and Surveillance	93.073			27,013	-
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	University of Texas Health Science Center	5NU27DD00115503	(20)	-
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	University of Texas Health Science Center	5NU27DD00115504	7,259	-
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	University of Texas Health Science Center	5NU27DD00115505	14,568	-
TOTAL BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH				21,807	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2020

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Capacity Building Assistance for High-Impact HIV Prevention	93.834			531,045	-
Centers for Disease Control and Prevention	93.U01			517,972	-
Centers for Disease Control and Prevention	93.U02	City of St. Louis	20-22	10,806	-
Centers for Disease Control and Prevention	93.U03	Missouri Department of Health and Senior Services	1919	59,113	-
COVID19-Emerging Infections Sentinel Networks	93.860	Olive View	1U01CK00048001	6,713	-
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)	93.323	Missouri Department of Health and Senior Services	HD1912A00001	33,472	-
HIV Prevention Activities_Health Department Based	93.940	Missouri Department of Health and Senior Services	HRSA1166	40,629	-
HIV Prevention Activities_Health Department Based	93.940	City of St. Louis Department of Health	11107110010	68,111	-
HIV Prevention Activities_Health Department Based	93.940	Missouri Department of Health and Senior Services	RFP30034901700449	37,922	-
TOTAL HIV PREVENTION ACTIVITIES_HEALTH DEPARTMENT BASED				146,662	-
Department of Health and Human Services					
Department of Health and Human Services	93.U04			44,623	-
Department of Health and Human Services	93.U05	St. Louis Effort for AIDS	PDS156548	(126)	-
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES				44,497	-
Food and Drug Administration					
Food and Drug Administration	93.U06			175,981	-
Health Resources and Services Administration					
Health Resources and Services Administration	93.U07	Health Research Inc.	15-0898-03	10,896	-
Trans-NIH Research Support	93.110	University of Texas Health Science Center At San Antonio	5H30MC240510700	25,767	-
Emergency Medical Services for Children	93.127	Cincinnati Children's Hospital Medical Center	5U03MC2268408	33,149	-
Emergency Medical Services for Children	93.127	Cincinnati Children's Hospital Medical Center	6U03MC226840901	158,080	-
TOTAL EMERGENCY MEDICAL SERVICES FOR CHILDREN				191,229	-
Grants to Increase Organ Donations	93.134	University of Arizona	5U13HS3058603	876	-
COVID19-Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.153			2,247	-
Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.153			(1,118)	-
Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.153			156,075	-
Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.153			1,157,777	140,928
TOTAL COORDINATED SERVICES AND ACCESS TO RESEARCH FOR WOMEN, INFANTS, CHILDREN, AND YOUTH				1,314,981	140,928
Sickle Cell Treatment Demonstration Program	93.365			366,804	196,151
Sickle Cell Treatment Demonstration Program	93.365			136,785	113,173
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	2H89HA000332400	453,989	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	2058	3,927	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	USDHHS - RYAN WHITE	811,120	-
TOTAL HIV EMERGENCY RELIEF PROJECT GRANTS				1,269,036	-
HIV Care Formula Grants	93.917	ARCW	DH1713A0001	269,264	-
HIV Care Formula Grants	93.917	Missouri Department of Health and Senior Services	RFA 1706	(66)	-
HIV Care Formula Grants	93.917	Missouri Department of Health and Senior Services	DH1907A0002	350,551	72,078
HIV Care Formula Grants	93.917	St. Clair County	05780063H-4	24,132	-
HIV Care Formula Grants	93.917	St. Clair County	75780031E-3	69,450	-
HIV Care Formula Grants	93.917	St. Clair County	RYAN WHITE HIV/AIDS	(1,266)	-
TOTAL HIV CARE FORMULA GRANTS				712,065	72,078
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	93.918			6,336	-
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	93.918			332,086	22,999
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	93.918			263,152	-

The accompanying notes are an integral are of this schedule.

Washington University Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2020

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Special Projects of National Significance	93.928			35,110	5,995
Special Projects of National Significance	93.928			343,042	-
Maternal and Child Health Services Block Grant to the States	93.994	Missouri Department of Health and Senior Services	B04MC30623	175,338	-
COVID19-Testing for the Uninsured	93.461			199,760	-
Office of Minority Health					
Community Programs to Improve Minority Health	93.137	St. Louis Integrated Health	1CPIMP1611360300	45,217	-
Office of Population Affairs					
Family Planning Services	93.217	Missouri Family Health Council	FPHPA006455	159,436	-
Family Planning Services	93.217	Missouri Family Health Council	FPHPA076285	21	-
Family Planning Services	93.217	Missouri Family Health Council	FPHPA006455	28,398	-
TOTAL FAMILY PLANNING SERVICES				187,855	-
Office of the Secretary of Health and Human Services					
Biomedical Advanced Research and Development Authority (BARDA)	93.U08	Bavarian Nordic	HHSO100201700019C	51,308	-
Biomedical Advanced Research and Development Authority (BARDA)	93.U09	Janssen Research and Development	HHSO100201500014C	25,298	-
Biomedical Advanced Research and Development Authority (BARDA)	93.U10	Summit (Oxford) Limited	HHSO100201700014C	9,819	-
Biomedical Advanced Research and Development Authority (BARDA)	93.U11	Terumo	HHSO100201600013C	1,792	-
Research on Research Integrity	93.085			-518	-
Substance Abuse and Mental Health Services Administration					
Substance Abuse and Mental Health Services_ Projects of Regional and National Significance	93.243			75,223	-
Substance Abuse and Mental Health Services_ Projects of Regional and National Significance	93.243			86,427	-
Substance Abuse and Mental Health Services_ Projects of Regional and National Significance	93.243			211,810	-
Substance Abuse and Mental Health Services_ Projects of Regional and National Significance	93.243			141,258	-
State Targeted Response to the Opioid Crisis Grants	93.788	University of Missouri, St. Louis	1H79TI0816701	100,658	-
State Targeted Response to the Opioid Crisis Grants	93.788	University of Missouri, St. Louis	1H79TI0816702	136,680	-
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES				8,589,438	559,119
OTHER FEDERAL PROGRAMS					
DEPARTMENT OF HOMELAND SECURITY					
Department of Homeland Security	97.U01	City of St. Louis	19DHFRV000010100	239,935	-
DEPARTMENT OF JUSTICE					
Office of Juvenile Justice and Delinquency Prevention					
Community-Based Violence Prevention Program	16.123	United Way of Greater St. Louis	2016MUMUK012	25,566	-
Community-Based Violence Prevention Program	16.123	United Way of Greater St. Louis	2017MUMUK006	13,877	-
Second Chance Act Reentry Initiative	16.812	Soulfisher Minsity	2018CYBX0018	65,078	-
Children of Incarcerated Parents	16.831	Father's Support Center	2014IGBX0005	-424	-
DEPARTMENT OF THE TREASURY					
Internal Revenue Service					
Low Income Taxpayer Clinics	21.008			93,127	-
INSTITUTE OF MUSEUM AND LIBRARY SERVICE					
Museums for America	45.301			52,661	-
National Leadership Grants	45.312			1,626	-
NATIONAL ARCHIVES AND RECORDS ADMINISTRATION					
National Archives and Records Administration					
National Historical Publications and Records Grants	89.003			7,032	-
National Archives and Records Administration	89.U01	National Film Preservation Foundation	FED17029	3	-
National Archives and Records Administration	89.U02	National Film Preservation Foundation	FED18022	7,762	-
NATIONAL ENDOWMENT FOR THE ARTS					
Promotion of the Arts Grants to Organizations and Individuals	45.024			25,000	-
NATIONAL ENDOWMENT FOR THE HUMANITIES					
Promotion of the Humanities Fellowships and Stipends	45.160			4,200	-
Promotion of the Humanities Division of Preservation and Access	45.149			69,826	32,130
Total Other Sponsored Programs from Other Federal Agencies				605,269	32,130
Total Other Sponsored Programs				9,457,198	591,249

The accompanying notes are an integral are of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2020

Cluster Title/Federal Grantor/Program Title	CFDA Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Student Financial Assistance Cluster					
DEPARTMENT OF EDUCATION					
Federal Supplemental Educational Opportunity Grant	84.007			1,088,576	-
Federal Work-Study Program	84.033			1,706,690	-
Federal Pell Grant Program	84.063			4,875,563	-
Teacher Education Assistance for College and Higher Education Grants	84.379			80,848	-
Federal Direct Student Loans					
Outstanding Loans as of July 1, 2019	84.268			-	-
New Loans Issued during 2020	84.268			75,261,596	-
Administrative Cost Allowance	84.268			-	-
Federal Perkins Loans					
Outstanding Loans as of July 1, 2019	84.038			25,519,303	-
New Loans Issued during 2020	84.038			-	-
Administrative Cost Allowance				-	-
DEPARTMENT OF HEALTH AND HUMAN SERVICES					
Health Professions Student Loans including Primary Care Loans/Loans for Disadvantaged Students					
Outstanding Loans as of July 1, 2019	93.342			114,564	-
New Loans Issued during 2020	93.342			-	-
Administrative Cost Allowance	93.342			-	-
Total Student Financial Assistance Cluster				108,647,140	-
Highway Safety Cluster					
DEPARTMENT OF TRANSPORTATION					
Police Traffic Services	20.600	Missouri Dept of Transportation	19DL02001	46,436	-
Police Traffic Services	20.600	Missouri Dept of Transportation	19DL02002	29,507	-
Police Traffic Services	20.6	Missouri Dept of Transportation	20DL02001	106,839	-
Total Highway Safety Cluster				182,782	-
TRIO Cluster					
DEPARTMENT OF EDUCATION					
TRIO - Student Support Services	84.042			480,060	-
Medicaid Cluster					
DEPARTMENT OF HEALTH AND HUMAN SERVICES					
Medical Assistance Program	93.778	Missouri Department of Health and Senior Services	ER100160099	\$ 62,783	\$ -
Total Federal Award Expenditures				689,251,613	54,807,349

The accompanying notes are an integral are of this schedule.

Washington University
Notes to Schedule of Expenditures of Federal Awards
For the Year Ended June 30, 2020

1. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards (the “Schedule”) summarizes the expenditures of Washington University (the “university”) under programs of the Federal Government for the year ended June 30, 2020. Expenditures of direct awards to the university are reported in total by program. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulation Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Therefore, some amounts presented in this schedule may differ from amounts presented in, or used in the preparation of, the basic financial statements. The university includes the amounts in the Schedule in the net assets without donor restrictions of the university’s Consolidated Statement of Activities for the year ended June 30, 2020.

The Schedule is prepared on the accrual basis of accounting. Catalog of Federal Domestic Assistance (“CFDA”) and pass-through numbers are provided when available. Negative amounts presented as expenditures represent subsequent period adjustments, transfers, or vendor credits. Expenditures are recognized following the cost accounting principles contained in the Uniform Guidance wherein certain types of expenditures are not allowable or are limited to reimbursement. Moreover, expenditures include a portion of costs associated with general university activities which are allocated to awards under negotiated formulas commonly referred to as facilities and administrative cost rates.

Federal Awards

For purposes of the Schedule, federal awards include all grants, contracts and similar agreements entered into directly by the university with agencies and departments of the Federal Government and all awards received as a subrecipient from nonfederal organizations pursuant to federal grants, contracts and similar agreements.

2. Facilities and Administrative Costs

The university recovers facilities and administrative costs under federal financial assistance programs using predetermined rates ranging from 25.5% to 57%. The university does not use the 10% de minimis cost rate but instead has negotiated the rates above with the Department of Health and Human Services through June 30, 2020.

3. Federal Student Loan Programs

The following schedule includes the SFA loan balances outstanding as of June 30, 2020:

Student Financial Aid	Federal CFDA Number	Outstanding Balances
U.S. Department of Education		
Federal Perkins Loan Program	84.038	19,407,823
U.S. Department of Health and Human Services		
Health Profession Student Loans, Primary Care Loans	93.342	65,828

Report on Compliance and on Internal Controls



Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

To the Board of Trustees of Washington University

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Washington University and its subsidiaries (the “university”), which comprise the consolidated statement of position as of June 30, 2020, and the related consolidated Statements of Activities and of Cash Flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated October 2, 2020.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the university’s internal control over financial reporting (“internal control”) as a basis for designing the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the university’s internal control. Accordingly, we do not express an opinion on the effectiveness of the university’s internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity’s financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether the university’s financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

PricewaterhouseCoopers LLP

St. Louis, Missouri
October 2, 2020



**Report of Independent Auditors on Compliance with Requirements
That Could Have a Direct and Material Effect on Each Major Program and on Internal
Control Over Compliance in Accordance with the Uniform Guidance**

To the Board of Trustees of Washington University

Report on Compliance for Each Major Federal Program

We have audited Washington University's (the university") compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on each of the university's major federal programs for the year ended June 30, 2020. The university's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal statutes, regulations and the terms and conditions of its federal awards applicable to its federal programs.

Auditors' Responsibility

Our responsibility is to express an opinion on compliance for each of the university's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about the university's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of the university's compliance.

Opinion on Each Major Federal Program

In our opinion, the university complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2020.

Report on Internal Control Over Compliance

Management of the university is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered the university's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report



on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the university's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. *A significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

PricewaterhouseCoopers LLP

St. Louis, Missouri
March 4, 2021

Schedule of Findings and Questioned Costs

Washington University
EIN# 43-0653611
Schedule of Findings and Questioned Costs
Year Ended June 30, 2020

Part I - Summary of Auditors' Results

Financial Statements

Type of auditors' report issued: Unmodified

Internal control over financial reporting:

Material weakness (es) identified? Yes No

Significant deficiency (ies) identified not considered to be material weaknesses? Yes None reported

Noncompliance material to financial statements noted? Yes No

Federal Awards

Type of auditors' report issued on compliance for major programs: Unmodified

Internal control over major programs:

Material weakness (es) identified? Yes No

Significant deficiency (ies) identified not considered to be material weaknesses? Yes None reported

Any audit findings disclosed that are required to be reported in accordance with Uniform Guidance Section 200.516(a)? Yes No

Identification of Major Programs:

CFDA Number(s)	Name of Federal Program or Cluster
Various	Research and Development Cluster
93.153	US Dept of Health and Human Services / Health Resources and Services Administration
Dollar threshold used to distinguish between Type A and Type B programs:	\$3,000,000
Auditee qualified as low-risk auditee?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

Washington University
EIN# 43-0653611
Schedule of Findings and Questioned Costs
Year Ended June 30, 2020

Part II – Financial Statement Findings

There are no financial statement findings to report.

Part III – Federal Award Findings and Questioned Costs

There are no federal award findings and questioned costs to report.

Summary Schedule of Prior Audit Findings

Washington University
Summary Schedule of Prior Audit Findings
Year Ended June 30, 2020

Part IV – Federal Award Findings

There were no federal award findings and questioned costs in the prior year.